



**Kingdom of Saudi Arabia
Saudi Health Council
Saudi Cancer Registry**

**Cancer Incidence Report
Saudi Arabia
2011**

Prepared by

Mrs. Amal Nasser Al.-Madouj
Mr. Mohammed Saleh Hayder
Mrs. Wafa Abdullah Al-Zahrani
Ms. Mona Mohammed Al-Shridah
Ms. Tahani Hussain Al-Shumrani

Reviewed by

Dr. Ali Saeed Al-Zahrani
Dr. Hind Mohammed Al-Mutlaq
Dr. Amer Naeem Radwi
Dr. Shouki Mohammed Bazarbashi

The SCR Scientific Committee Members

Dr. Ali Saeed Al-Zahrani	(Chairman)
Dr. Hind Mohammed Al-Mutlaq	(The Acting Director of SCR)
Dr. Mushabab Ali Asiri	(Regional Director of Central Region)
Dr. Hassnah Ali Al-Ghamdi	(Regional Director of Western Region)
Dr. Amal Mohammed Al-Behani	(Regional Director of Madinah and Northern Region)
Dr. Abdrrhman Ali Al-Shehri	(Regional Director of the Southern Region)
Prof. Hassan Yousef Al-Idrisi	(Regional Director of the Eastern Region)
Dr. Mohammed Yahya Saeedi	(Ministry of Health)
Dr. Amer Naeem Radwi	(Health Affairs- Ministry of National Guard)
Dr. Abdulaziz Saleh Abahussi	(Medical Services- Security Forces)
Dr. Ali Matar Al-Zahrani	(Medical Services- Military Forces)
Dr. Shouki Mohammed Bazarbshi	(KFSH & RC)
Dr. Abdulziz Abdullah Al-Saif	(Ministry of Education, KSU)
Dr. Abdulrahem Toran Gari	(Private Hospital)

Foreword

I am very pleased to present the Annual Cancer Incidence Report for Saudi Cancer Registry (SCR) for the year 2011. It sums up the efforts and full dedication to provide cancer data during a complete year. The Saudi Cancer Incidence reports which have been released since the registry was established in 1994 contributed in supporting the fight against cancer by providing genuine scaling of its epidemiology and by providing those responsible for cancer control and prevention programs with accurate and detailed data which reflect the real situation of cancer in the kingdom and in identifying the most prevalent types of cancer according to gender, age and geographical distribution. These reports are of great value for decision makers in planning to develop new cancer treatment and prevention centers and for scientific research and conferences held in different regions of the country, which goes in line with health strategies and objectives set by the Saudi Health Council.

The Council works continuously to assure effective performance and full administrative and technical support for the registry. It further deploys the published statistics to set national priorities for cancer control and prevention programs in coordination with different health sectors.

In an effort of SCR and through its national committee, one of the Saudi Health Council, approved a new national strategy for cancer prevention and control. It agreed to establish the National Cancer Center (NCC) with the function to set standards and protocols for cancer treatment and prevention to be implemented by different health sectors. The NCC will supervise implementation of the national strategy and setting the medical and research standards with the aim of better health care services provided to cancer patients. It will help in the exchange of expertise between medical centers in different government sectors, raising the level of medical expertise and professional performance and localization of national competencies.

In conclusion, what we see as a significant development in the health field in our beloved country is due to the blessings of the all mighty Allah and the support of our government under the leadership of the Custodian of the Two Holy Mosques and the Crown Prince and the Crown to the Crown Prince –May Allah protect them- who save no effort to offer best service and comfort to the citizens of Saudi Arabia. We like to thank all employees of health sectors, institutions and charities who gave cancer a great care in establishing treatment and awareness programs for cancer in the kingdom.

General Secretary of SHC.

Dr. Yagob Al-Mazrou



Introduction

This is the fifteenth incidence report published by the Saudi Cancer Registry. Previous publications include the Incidence Reports for the years -1994 2000 -1999 ,1998 - 1997 ,1996 and yearly until 2010.

The structure of this report can be outlined as follows:

Part I-Materials and Methods

This part of the report contains information about the background of the Saudi Cancer Registry and methods used in collecting and analyzing the data. We present the basics of coding and classification of tumor topography, morphology and extent of disease at the time of diagnosis. Also we describe the software programs we have used to analyze the data.

Part II-Overview of Cancer Incidence

Part II contains figures and tables that show overall cancer incidence in Saudi Arabia for the year 2011. We present these figures and tables mainly by sex and in certain areas we have it analyzed by different age groups. There are bar charts representing the age distribution of cancer incidence for the year 2011 among Saudis by sex and age groups. We present incidence and morphology tables for the most common types of cancers among adults and children. In addition, tables, list the total number of cases, the Age-Standardized Incidence Rate (ASR) per 100,000 population, Crude Incidence Rate (CIR) and Cumulative rates by primary site and sex. Separate bar charts depict the most common types of cancer, by sex.

Part III- Cancer Incidence for Most Common Sites 2011

In this part the incidence of the most common cancers among Saudi males and females are outlined. A standardized layout presents data for all patients and for both sexes where applicable. For each selected site the number and the percentage of all newly diagnosed cases for the year 2011, the ASR for each sex and the specific cancer rank for both sexes are presented. In addition, ASR for the specified cancer among Saudis is compared with ASR among other populations from selected countries.

Part IV-Cancer Incidence among Non-Saudis

This part presents the incidence of cancer cases among Non-Saudis including the most common types of cancer. The analysis of the Non-Saudis is performed separately due to the nature of the expatriate population in Saudi Arabia in which a large part of the population, particularly among males, falls in the 25 - 44 age groups.

Part V-Incidence Tables

Part V contains the following detailed tables for all newly diagnosed cancer types among Saudis and Non-Saudis for 2011.

- Distribution of cancer cases among Saudis by age group and sex.
- Distribution of cancer cases among Non- Saudis by age group and sex.
- Cancer Incidence (per 100,000 populations) among Saudis by age group and sex.
- Cancer Incidence (per 100,000 populations) among Non-Saudis by age group and sex.
- Age-standardized incidence rate and relative frequencies among Saudis by cancer site, sex.
- Number of In Situ Cases, Myelodysplastic Syndrome and Myeloproliferative Disease among Saudis and Non-Saudis.

Part VI- Arabic Summary

Part VI Contains Arabic Summary of Cancer Statistics in Saudi Arabia for the Year 2011.

Table of Contents

Foreword.....	3
Introduction	5
PART I.....	9
Background on Saudi Arabia.....	10
Saudi Cancer Registry	10
Definitions of Statistical Terms.....	13
PART II.....	15
Reported Cancer Incidence cases in Saudi Arabia 2011	16
Adult Cancers in Saudi Arabia, 2010 (above 14 years)	21
Childhood Cancers in Saudi Arabia 2011 (14 years and below).....	24
International Comparison of Age-Standardized Incidence Rates.....	27
PART III	28
Cancer Incidence for Most Common Sites, 2011	30
Female Breast (C 50).....	31
Colo-rectal (C18-C20).....	33
Thyroid (C73).....	35
Non-Hodgkin Lymphoma (C82-C85; C96)	37
Leukemia (C91-C95)	39
Liver (C22).....	41
Lung (C33-C34).....	43
Hodgkin Disease (C81).....	45
Skin (C44)	47
Corpus Uteri (C54)	49
Prostate (C61)	51
Stomach (C16).....	53
Kidney (C64)	55
Brain(C70-C72).....	57
Bladder (C67).....	59
Sources	61
PART IV	62
Cancer Among Non-Saudi Population, 2011	64

PART V 66

Table 5.1.1	Age Distribution of Cancer Cases among Saudi Males, 2011	67
Table 5.1.2	Age Distribution of Cancer Cases among Saudi Females, 2011	68
Table 5.1.3	Age-Specific Incidence Rate (AIR), Age-Standardized Incidence Rate (ASR) among Saudi Males (per 100,000) by Primary Site and Age Groups , 2011	69
Table 5.1.4	Age-Specific Incidence Rate (AIR), Age-Standardized Incidence Rate (ASR) among Saudi Females (per 100,000) by Primary Site and Age Groups, 2011	70
Table 5.4.1	Number of Cancer Cases among Non-Saudi Males by Primary Site and Age Groups, 2011	71
Table 5.4.2	Number of Cancer Cases among Non-Saudi Females by Primary Site and Age Groups, 2011	72
Table 5.4.3	Age-Specific Incidence Rate (AIR), Age-Standardized Incidence Rate (ASR) among Non-Saudi Males (per 100,000) by Primary Site and Age Groups , 2011	73
Table 5.4.4	Age-Specific Incidence Rate (AIR), Age-Standardized Incidence Rate (ASR) among Non-Saudi Females (per 100,000) by Primary Site and Age Groups, 2011	74
Table 5.5.1	Number of Cases by Primary Site and Years among Saudi Males, 1994-2011	75
Table 5.5.2	Number of Cases by Primary Site and Years among Saudi Females, 1994-2011	76
Table 5.5.3	Age Standardized Incidence Rate by Primary Site and Years among Saudi Males, 1994-2011	77
Table 5.5.4	Age Standardized Incidence Rate by Primary Site and Years among Saudi Females, 1994-2011	78
Table 6.1	Number of In Situ Cases among Saudis and Non-Saudis, 2011	79
Table 6.2	Number of Myelodysplastic Syndromes and Chronic Myeloproliferative Disorders among Saudis and Non-Saudis, 2011	

PART VI 80

Arabic Summary of Cancer Statistics in Saudi Arabia for the Year 2011.....	83-81
--	-------



PART I
MATERIALS AND METHODS

Background on Saudi Arabia

Saudi Arabia is a vast country extending over four-fifths of the Arabian Peninsula. It stretches from the Arabian Gulf in the east to the Red Sea in the west. It is approximately 2,149,700* square kilometers in area and is divided into 13 administrative regions (Figure 1.1).



Figure 1.1 Administrative Regions of Saudi Arabia

The Saudi national population for year 2011 was 19,405,685**. Of these 9,743,626 (50.2%) were males and 49.8% 9,662,059 were females. The Non-Saudi population in 2011 was 8,970,670**, of these 6,297,737 (70.2%) were males and 2,672,933 (29.8%) females. Figures 1.2 and 1.3 show the Saudi and Non-Saudi population pyramids by sex and age group respectively.




Figure 1.2 Population Pyramid of Saudis (%) by Sex and Age Group, 2011




Figure 1.3 Population Pyramid of non-Saudis (%) by Sex and Age Group, 2011

Saudi Cancer Registry

The Saudi Cancer Registry (SCR) is a population-based registry established in 1992 under the authority of the Ministry of Health (MOH) by the order of His Excellency the Minister of Health. The SCR was moved to the Saudi Health Council in 1435 (2014). The SCR commenced reporting cancer cases from 01 January 1994.

Objectives

The primary goal of the SCR is to define the population-based incidence of cancer in Saudi Arabia. Another objective is to support the early detection programs and cancer screening programs, as well as cancer research projects through providing accurate cancer data.

Organizational Structure

The representatives from the MOH, King Faisal Specialist Hospital and Research Center (KFSH&RC), and the Medical Services Departments of the Ministry of Defense and Aviation, Ministry of Interior, Ministry of National Guard, King Saud University. The representatives are charged with the responsibility of overseeing the SCR's establishment, defining demographic and cancer related data to be collected, approving data requests, and reporting findings, as well as disseminating information collected while ensuring the confidentiality of all data reported to the SCR.

* Source: Demographic and Health Indicators for Countries of the East Mediterranean, WHO, Regional Office for the EM, 1999

** Source: Central Department of Statistics & Information, Ministry of Economy and Planning

The SCR Main Office, including administrative and technical staff, is located in the Saudi Health Council in Riyadh. Additionally, five regional branches and five hospital-based offices were set up to ensure comprehensive data collection from all over the Kingdom (Figure 1.4).

Regional Offices

1. Central Region: King Fahad Medical City in Riyadh, covering Riyadh, Qassim, and Hail Health Regions.
2. Eastern Region: King Fahad Hospital of the University, Al Khobar, covering Dammam, Al Ahsa, and Hafr Al-Batin Health Regions.
3. Western Region: King Abdulaziz Hospital and Cancer Center, Jeddah, covering Jeddah, Makkah, Taif and Qunfudah Health Regions.
4. Southern Region: Asir Central Hospital, Abha, covering Asir, Baha, Najran, Jazan and Bisha Health Regions.
5. Madinah/Northern Region: Maternity and Children Hospital, Madinah, covering Madinah, Tabuk, Jouf and Northern Health Regions.

Offices at the Medical Service Division or Oncology Department of the following establishments

6. King Faisal Specialist Hospital & Research Centre, Riyadh
7. Ministry of Defense and Aviation, Armed Forces Hospitals, Riyadh
8. Ministry of Interior, Security Forces Hospital, Riyadh
9. Ministry of National Guard Hospitals, King Abdulaziz Medical City, Princess Norah Oncology Center, Jeddah.
10. King Khalid University Hospital, Riyadh.

Each of the SCR office operates under the supervision of directors who are responsible for the daily management. Staffing consists of tumor registrars and secretarial staff. The SCR Main Office indirectly supervises the regional offices to ensure accuracy and quality of data collected from all regions. Quality control processes include verification of site, morphology, and staging information as well as case linkage (tumor and patient), and consolidation of data. The Main Office also prepares annual reports for dissemination of information to the medical community, government establishments, international organizations and the media.




Figure 1.4 Organizational Chart of the Saudi Cancer Registry of Saudi Arabia

Format

The format of the current report is similar to the previous reports.

Data Management

A ministerial decree has categorized cancer as a mandatory notifiable disease. This ensures the opportunity for comprehensive data collection. The SCR strives for full access to cancer data from all Ministry of Health, governmental and private hospitals, as well as clinics and laboratories throughout the Kingdom. Cancer data are abstracted from patients' medical records, based on clinical and/or histopathological diagnosis, by SCR-trained cancer registrars.

The data abstract includes personal identification (name, ID Number, sex, age), demographic information (address, telephone number, nationality), and tumor details (diagnosis date, primary site, histology, behavior, grade, stage, basis of diagnosis). The primary site (topography) and histology (morphology) of the malignancies are identified and coded according to the International Classification of Diseases for Oncology 3rd Edition (ICD-O-3), published by the World Health Organization (WHO), 2000.

Effective from year 2001, changes were made in coding of cancer types and behaviors as well as staging according to International guidelines. The new SEER Summary Stage 2000 guidelines should result in increased accuracy and consistency in the coding of stage. There are some differences in the timing rules for determining stage and some sites are coded differently using the new guidelines.

However, the new criteria and guidelines should improve the usefulness of staging as a predictor of prognosis and survival as the changes reflect a new understanding of the natural history of cancer.

The new guidelines, SEER Summary Stage Manual 2000, are available on the web at:

<http://seer.cancer.gov/tools/ssm/>

Cases diagnosed on or after 01 January 2008 are classified according to the updated ICD-O-3. Improvements in the understanding of cancer pathology over the last decade are reflected in the changes to ICD-O-3.

While there have not been any changes in the primary site codes, there are significant changes regarding histology (cell types). Leukemias and lymphomas, particularly are affected. Some cases that were previously considered benign are now counted as malignant. Also small number of cancers that were previously coded as borderline tumors are now considered benign.

Counts of ovarian cancers, lymphomas and leukemias as well as some hematopoietic diseases will change due to changes in either reportability or definition. However, as with the new staging

guidelines, the ICD-O changes reflect advances in the understanding of the pathology and behavior of cancers.

It should be noted that ICD-O-3 codes are converted to ICD-10 for analysis purposes. Since the WHO has not yet converted the ICD-10 hematopoietic disease behavior changes, our software, CanReg 4.33, cannot include these cases for analysis and they have been excluded.

Every effort is made to accurately code patient and tumor information, to ensure that all data can be reviewed, linked, and consolidated, as appropriate, so that each malignancy is counted only once for statistical analysis. The computer software programs used for data entry and incidence tables output are CanReg 4.33, developed by the International Agency for Research on Cancer, (IARC) Lyon, France.

The second part of the report includes the overall cancer incidence in Saudi Arabia and the relevant epidemiological and clinic pathological details for the 15 most common cancers among Saudi nationals for the year 2011.

For each cancer site, the number and the percentage of all newly diagnosed cases for the year 2011, the age-standardized incidence rate (ASR) per 100,000 populations for each sex, and the specific cancer rank in comparison to all cancers for both sexes are presented.

Useful international statistics for the specified cancer include the ranking of the cancer worldwide. The source for this information is summarized in page 66.

The relevant data incorporate details for all patients presented over the year 2011. For each cancer there are five figures:

1. An arithmetic line graph represents the age-specific incidence rate (AIR) for all age groups at five-year intervals. The graph is plotted by sex, where applicable.
2. A table lists the percentages of the most common histology sub-types for each specific cancer.
3. A pie chart shows the distribution of the clinical stages of each cancer such as localized, regional, distant metastasis and unknown.
4. A bar chart shows regional distribution of ASR for particular cancer across the administrative regions by males and females.
5. A bar chart shows comparison of age-standardized incidence rate (ASR) for each cancer type in Saudi Arabia with ASR in selected countries.

Notification

The data included in this report were abstracted up to March 2015. The incident cases which were identified after this date (late reporting) will be noted in subsequent incidence reports. It is anticipated that the number of late-reported cases will decrease as case ascertainment processes are improved.

Moreover we don't have up to date statistics because we have to wait until all of the data from the regional cancer branches in Saudi Arabia has been collected before we can publish the annual incidence report. Also, the process of registering a cancer is complicated and there are a number of processes in place to ensure the data is of a high quality. This means there is usually a delay of around 3-2 years before the data is complete enough to be published.

Definitions of Statistical Terms

Age-Specific Incidence Rate (AIR)

The number of cancer cases occurring during a specific period in a population of a specific age and sex group, divided by the number of midyear population of that age and sex group.

Crude Incidence Rate (CIR)

The crude incidence rate for a cancer site is the total number of cases registered as a proportion of the total population. It denotes the approximate number of cases occurring in each 100,000 individuals. All rates are thus, expressed as per 100,000 population.

Cancer rates vary greatly with age and the crude rate is strongly influenced by the demographic structure of the population. Hence, if the population structure changes over time the crude rate over that period may be artificially altered. It is not appropriate to compare crude rates across geographical areas of cancer registries with different population age structures. Therefore, in order to assess time trends in registration data or compare incidence across geographical areas or between registries it is necessary to first standardize the rates with respect to age.

Age-Standardized Rate (ASR)

The Age-standardized rate is a summary measure of a rate that a population would have if it had a standard age structure. Standardization is necessary when comparing several populations that differ with respect to age structure. The most frequently used standard population is the World Standard Population (see below). The calculated incidence is known as the World Standardized Incidence Rate. The rate is expressed per 100,000 populations.

Age Class	Population
0 - 4	12,000
5 - 9	10,000
10 - 14	9,000
15 - 19	9,000
20 - 24	8,000
25 - 29	8,000
30 - 34	6,000
35 - 39	6,000
40 - 44	6,000
45 - 49	6,000
50 - 54	5,000
55 - 59	4,000
60 - 64	4,000
65 - 69	3,000
70 - 74	2,000
75 +	2,000
Total	100,000

* Doll R. Payne P. Waterhouse J. Cancer Incidence in Five Continents Vol. I. International Union Against Cancer. 1966

Cumulative Incidence rate

Cumulative incidence rate is the probability or risk of individuals developing the disease during a specified period. For cancer, it is expressed as the number of new born children (out of 100, or 1000) who would be expected to develop a particular cancer before the age of 65 (or 70, or 75) if they had the rates of cancers currently observed. Like the age standardized rate, it permits comparison between populations of different age structures. In this report the age ranges 0-64 and 0-74 years are used. The cumulative rate is the summation of the cancer age-specific rates; which are computed for five-year age intervals. The cumulative rate is five times the sum of the age-specific rates calculated over the five-year age groups.

ICD - 10

The World Health Organization's International Classification of Diseases, tenth edition.

ICD - O - 3

The World Health Organization's International Classification of Diseases for Oncology, 3rd Edition has been the standard coding system for neoplasms for over 25 years. The coding system includes a four character code for primary site, a four-digit numeric code for cell type, one-digit code for behavior and a one-digit code for tumor aggressiveness (grade).

Incidence rate

An incidence rate is defined as the rate at which a new event occurs in a population. It is calculated as the number of new cases of disease arising in a population over a defined time period, divided by the population at risk of developing that disease.

Mean

The simple mathematical average of two or more numbers.

Median

The midpoint of the range numbers that are arranged in order of value.

Metastasis

Metastasis is the distant spread of cancer from its original site to other organs of the body, including lymph nodes, skeletal and or visceral organs.

Range

It is the difference between the maximum and minimum values in a set of observations.

Rank

This measure reflects the importance of a specific cancer site relative to other sites, in terms of the number of registrations. Ranking illustrates the most and least frequent cancer sites in a population according to their frequency.

Ratio

It is the relation between two quantities. The first quantity as numerator and the second as denominator

Relative Frequency

This statistic is defined as the number of specific cancer cases registered relative to the total number of all cancer. It is expressed as a percentage.

Summary Stage

Staging is the grouping of cancer cases into broad categories based on the extent of disease.

PART II
OVERVIEW OF CANCER INCIDENCE
2011

Reported Cancer Incidence Cases in Saudi Arabia, 2011

Between January 01 and December 31, 2011, the total number of cancer incidence cases reported to the Saudi Cancer Registry (SCR) was 14,776. Over all cancer affected 6,870 (46.6%) males and 7,870 (53.4%) females, with a male to female ratio of 100:87. Total of 11,165 cases were reported among Saudi, and 3,499 among Non-Saudis and 112 of unknown nationality.

The total number of cases excluded from analysis include 112 cases of unknown nationalities, other exclusions were 366 in situ cases; the current software program CanReg-4 version 4.33, does not include in situ cases in the statistical analysis. Also, 77 were ICD-O-3 coded cases that failed to convert to ICD-10 codes as described in the Data Management (see page 12 and page 92). This puts the total number of exclusions from the analysis as 554 cases. Table 2.1 illustrates the distribution of the cases by sex, nationality and cancer behavior.

Diagnosis of malignancy was confirmed histologically in 88.4% of the cases, and haematological & cytologically in 6.1% of cases. Clinically confirmed cases were 0.2%, radiologically confirmed cases were 2.3%, cases confirmed by death certificate were 2.4% and the method of diagnosis was unknown for 0.6% of the cases.

As shown on Table 2.1, 14,222 cases were analyzed, of which 10,869 (76.4%) were Saudis and 3,353 (23.5%) were Non-Saudis. Among the Saudis 4,913 (45.2%) were male and 5,956 (54.7%) were female. The male to female ratio was 100:87. The crude incidence rate (CIR) of all cancers among Saudi population was 65.0/100,000 (50.5/100,000 among males and 61.7/100,000 among females). The overall age-standardized incidence rate (ASR) for Saudis was 78.8/100,000 in males and 90.1/100,000 in females.

For all sites, the age-specific incidence rate (AIR) increased with age for both males and females. After the age of 64 years, the increase was nearly one and 1.6 fold with male to female ratio 133:100. The median age at diagnosis for men was 59 years; range (0 -120) and 51 years for women; range (0-111).

	Saudis			Non-Saudis			Unknown Nationality			All
	Male	Female	Total	Male	Female	Total	Male	Female	Total	Total
Analyzed *	4913	5956	10869	1690	1663	3353	0	0	0	14222
Invasive	4955	5980	10935	1698	1666	3364	52	59	111	14410
In Situ	113	117	230	51	48	135	1	0	1	366
ICD-10 **	42	24	66	8	3	11	0	0	0	77
Total	5068	6097	11165	1749	1714	3499	53	59	112	14776

Table 2.1 Distribution of Cancer Cases in Saudi Arabia by Nationality and Sex, 2011

* Unknown nationalities, in situ cases, and ICD-10 conversion failures are excluded from analyses
 ** ICD-10 conversion failure

Cancer among Saudis 2011

As explained earlier the total numbers of cancer cases analyzed among Saudis during the year 2011 were 10,869. Following are figures presenting the percentage distributions of (cancer incidence) and most frequent types of cancers among Saudis by sex and age-group.




Figure 2.1 Percentage Distribution of Cancer Incidence among Saudis by Sex according to Age Group, 2011




Figure 2.2 Percentage Distribution of Most Frequent Types of Cancer by Sex and age-groups among Saudis, 2011

Cancer	No.	%
Breast	1606	14.8
Colorectal	1194	11.0
Thyroid	800	7.4
NHL	744	6.8
Leukemia	697	6.4
Liver	488	4.5
Lung	452	4.2
Hodgkin Disease	341	3.1
Skin	333	3.1
Corpus Uteri	318	2.9

Table 2.2 Ten Most Common Cancers among Saudis, 2011 (All Ages)




Figure 2.3 Ten Most Common Cancers among Saudis by Sex, 2011




Figure 2.4 Age - Specific Incidence Rate (AIR) for All Cancers among Saudis, 2011

ICD-10	Site	Male						Females					
		No.	%	Crude	ASR	Cumulative Rate		No.	%	Crude	ASR	Cumulative Rate	
				Rate	World	0-64	0-74			Rate	World	0-64	0-74
C00	Lip	8	0.2	0.1	0.1	0	0.1	7	0.1	0.1	0.1	0	0.2
C01-C02	Tongue	44	0.9	0.5	0.7	0.3	1.1	52	0.9	0.5	0.9	0.6	1
C03-C06	Mouth	41	0.8	0.4	0.7	0.2	0.8	46	0.8	0.5	0.8	0.4	0.9
C07-C08	Salivary glands	14	0.3	0.1	0.2	0.1	0.2	22	0.4	0.2	0.3	0.2	0.3
C09	Tonsil	4	0.1	0	0.1	0	0	1	0	0	0	0	0
C10	Other Oropharynx	3	0.1	0	0	0	0	1	0	0	0	0	0
C11	Nasopharynx	121	2.5	1.2	1.8	1.2	2.1	45	0.8	0.5	0.6	0.5	0.6
C12-C13	Hypopharynx	9	0.2	0.1	0.2	0	0.2	16	0.3	0.2	0.3	0.2	0.3
C14	Pharynx unspec.	3	0.1	0	0	0	0	2	0	0	0	0	0
C15	Oesophagus	76	1.5	0.8	1.3	0.5	1.5	58	1	0.6	1	0.3	1.2
C16	Stomach	162	3.3	1.7	2.8	1.3	3.4	133	2.2	1.4	2.3	1.1	2.7
C17	Small intestine	35	0.7	0.4	0.6	0.3	0.6	35	0.6	0.4	0.6	0.3	0.6
C18	Colon	378	7.7	3.9	6.6	3.6	8	342	5.7	3.5	5.7	3.7	6.3
C19-C20	Rectum	279	5.7	2.9	4.7	2.6	5.7	195	3.3	2	3.3	2.2	3.9
C21	Anus	11	0.2	0.1	0.2	0.1	1.6	15	0.3	0.2	0.3	0.1	0.3
C22	Liver	330	6.7	3.4	6.1	2.6	7.5	158	2.7	1.6	2.9	1.4	3.7
C23-C24	Gallbladder etc.	73	1.5	0.7	1.3	0.5	1.5	90	1.5	0.9	1.6	0.8	1.9
C25	Pancreas	128	2.6	1.3	2.3	1.2	2.8	77	1.3	0.8	1.4	0.7	1.8
C30-C31	Nose, sinuses etc.	8	0.2	0.1	0.1	0.1	0.1	3	0.1	0	0	0	0
C32	Larynx	70	1.4	0.7	1.3	0.7	1.7	6	0.1	0.1	0.1	0.1	0.2
C33-C34	Trachea,Bronchus,Lung	343	7	3.5	6.4	2.6	8.1	109	1.8	1.1	1.9	1.1	2.2
C37-C38	Other Thoracic organs	21	0.4	0.2	0.3	0.1	0.3	7	0.1	0.1	0.1	0.1	0.2
C40-C41	Bone	71	1.4	0.7	0.8	0.4	0.5	58	1	0.6	0.6	0.4	0.4
C43	Melanoma of Skin	16	0.3	0.2	0.3	0.1	0.2	15	0.3	0.2	0.2	0.1	0.3
C44	Other Skin	208	4.2	2.1	3.6	1.2	3.4	125	2.1	1.3	2.2	1.1	2.2
C45	Mesothelioma	12	0.2	0.1	0.2	0.1	0.2	1	0	0	0	0	0.1
C46	Kaposi sarcoma	19	0.4	0.2	0.3	0.2	0.4	6	0.1	0.1	0.1	0.1	0.1
C47;C49	Connective,Soft tissue	77	1.6	0.8	0.9	0.5	1	72	1.2	0.7	0.9	0.6	0.8
C50	Breast	16	0.3	0.2	0.3	0.1	0.4	1590	26.7	16.5	23.4	17.9	25.5
C60	Penis	0	0	0	0	0	0	-	-	-	-	-	-
C61	Prostate	311	6.3	3.2	6	1.6	6.9	-	-	-	-	-	-
C62	Testis	80	1.6	0.8	0.8	0.6	0.6	-	-	-	-	-	-
C63	Other male genital	6	0.1	0.1	0.1	0.1	0.1	-	-	-	-	-	-
C51	Vulva	-	-	-	-	-	-	7	0.1	0.1	0.1	0	0.1
C52	Vagina	-	-	-	-	-	-	4	0.1	0	0.1	0	0.1
C53	Cervix Uteri	-	-	-	-	-	-	114	1.9	1.2	1.7	1.1	1.8
C54	Corpus Uteri	-	-	-	-	-	-	318	5.3	3.3	5.8	3.5	7.5
C55	Uterus unspec.	-	-	-	-	-	-	41	0.7	0.4	0.7	0.5	1.8
C56	Ovary	-	-	-	-	-	-	198	3.3	2.1	3.1	1.7	3.9
C57	Other Female Genital	-	-	-	-	-	-	12	0.2	0.1	0.2	0.2	0.2
C58	Placenta	-	-	-	-	-	-	9	0.2	0.1	0.1	0.1	0.1
C64	Kidney	178	3.6	1.8	2.9	1.6	3.1	112	1.9	1.2	1.7	1.2	2
C65	Renal Pelvis	3	0.1	0	0	0	0	2	0	0	0	0	0.1
C66	Ureter	5	0.1	0.1	0.1	0.1	0.1	2	0	0	0	0	0.1
C67	Bladder	182	3.7	1.9	3.3	1.6	3.9	52	0.9	0.5	1	0.4	1.4
C68	Other Urinary organs	1	0	0	0	0	0.1	0	0	0	0	0	0
C69	Eye	20	0.4	0.2	0.2	0.1	0.1	19	0.3	0.2	0.2	0.1	0.2
C70-C72	Brain, Nervous system	170	3.5	1.7	2.2	1.4	2.3	99	1.7	1	1.2	0.7	1.1
C73	Thyroid	154	3.1	1.6	2.2	1.4	2.6	646	10.8	6.7	8.1	6.2	7.8
C74	Adrenal gland	13	0.3	0.1	0.1	0.1	0.1	5	0.1	0.1	0	0	0
C75	Other Endocrine	8	0.2	0.1	0.1	0.1	0.1	4	0.1	0	0.1	0	0.1
C81	Hodgkin disease	184	3.7	1.9	1.9	1.2	1.5	157	2.6	1.6	1.7	1.1	1.6
C82-C85;C96	Non-Hodgkin lymphoma	432	8.8	4.4	6.4	3.6	6.8	312	5.2	3.2	4.8	2.5	5.5
C88	Immunoproliferative dis.	1	0	0	0	0	0	0	0	0	0	0	0
C90	Multiple Myeloma	50	1	0.5	0.9	0.4	1	47	0.8	0.5	0.8	0.5	0.9
C91	Lymphoid Leukaemia	202	4.1	2.1	2.3	1.3	1.8	142	2.4	1.5	1.6	0.9	1.1
C92-C94	Myeloid Leukaemia	148	3	1.5	2	1.2	1.9	176	3	1.8	2.2	1.6	2
C95	Leukaemia unspec.	16	0.3	0.2	0.2	0.1	0.2	13	0.2	0.1	0.2	0.1	0.2
Other	Other unspecified	169	3.4	1.7	2.8	1.2	2.9	178	3.0	1.8	3.0	1.6	3.5

Table 2.3 Number, Percentage, ASR, CIR and Cumulative Rates (per 100,000) of New Cases by Primary Site and Sex among Saudis, 2010

Adult Cancers in Saudi Arabia, 2011 (>14 years)

Between January and December 2011, the total number of adult cancer incidence cases reported was 14011. Overall cancer was more in females than in males. Cancer affected 6,459 (46.1%) males and 7,552 (53.9%) female with male to female a ratio of 86:100. Of all cases, there were 10,438 Saudis, 3,463 of Non-Saudis and 110 of unknown nationalities. As shown on table 2.4.1, the total number of analyzed cases were 13,505.

	Saudis			Non-Saudis			Unknown Nationality			All
	Male	Female	Total	Male	Female	Total	Male	Female	Total	Total
Analyzed *	4508	5644	10152	1690	1663	3353	0	0	0	13505
Invasive	4545	5665	10210	1698	1666	3364	51	58	109	13683
In Situ	113	115	228	51	48	99	1	0	1	328
ICD-10 **	37	21	58	8	3	11	0	0	0	69
Total	4658	5780	10438	1749	1714	3463	52	58	110	14011

Table 2.4.1 Distribution of Reported Adult Cancer Cases in Saudi Arabia by Nationality and Sex, 2011

Cancer	No.	%
Breast	1589	14.6
Colorectal	1192	11.0
Thyroid	795	7.3
NHL	667	6.2
Leukemia	433	4.0
Liver	471	4.3
Lung	450	4.1
Skin	332	3.1
Corpus Uteri	318	2.9
Prostate	310	2.9

Table 2.4.2 Ten Common Cancer among Saudi Adults, 2011




Figure 2.6 Ten Most Common Cancers among Saudi Adults by sex, 2011

Primary Site	Code	Morphology	Male	%	Female	%
Breast	8500	Infiltrating Duct Carcinoma, NOS	12	70.6	1218	76.5
	8520	Lobular carcinoma, NOS	0	0.0	88	5.5
	8010	Carcinoma, NOS	0	0.0	56	3.5
	8000	Neoplasm, malignant	1	5.9	53	3.3
	8522	Infiltrating duct and lobular carcinoma	0	0.0	41	2.6
	8523	Infiltrating duct mixed with other types of carcinoma	0	0.0	23	1.4
	8510	Medullary carcinoma, NOS	0	0.0	19	1.2
	8480	Mucinous adenocarcinoma	0	0.0	13	0.8
	9020	Phyllodes tumor, malignant	0	0.0	12	0.8
		Others	4	23.5	69	4.3
Colorectal	8140	Adenocarcinoma, NOS	518	78.5	421	77.8
	8480	Mucinous adenocarcinoma	43	6.5	38	7.0
	8263	Adenocarcinoma in tubulovillous adenoma	14	2.1	16	3.0
	8000	Neoplasm, malignant	14	2.1	10	1.8
	8261	Adenocarcinoma in villous adenoma	11	1.7	12	2.2
	8210	Adenocarcinoma in adenomatous polyp	15	2.3	6	1.1
	8490	Signet ring cell carcinoma	10	1.5	8	1.5
	8010	Carcinoma, NOS	7	1.1	7	1.3
		Others	28	4.2	23	4.3
Thyroid	8260	Papillary adenocarcinoma, NOS	75	48.1	312	48.1
	8340	Papillary carcinoma, follicular variant	16	10.3	115	17.7
	8341	Papillary microcarcinoma	7	4.5	73	11.3
	8344	Papillary carcinoma, columnar cell	7	4.5	38	5.9
	8343	Papillary carcinoma, encapsulated	7	4.5	28	4.3
	8335	Follicular adenocarcinoma, NOS	9	5.8	13	2.0
	8290	Oxyphilic adenocarcinoma	3	1.9	13	2.0
	8335	Follicular carcinoma, minimally invasive	4	2.6	11	1.7
		Others	28	17.9	45	6.9
NHL	9680	Malignant lymphoma, large B-cell, diffuse, NOS	182	47.3	158	54.1
	9591	Malignant lymphoma, non-Hodgkin, NOS	15	3.9	20	6.8
	9590	Malignant lymphoma, NOS	19	4.9	15	5.1
	9700	Mycosis fungoides	16	4.2	18	6.2
	9699	Marginal zone B-cell lymphoma, NOS	15	3.9	15	5.1
	9670	Malignant lymphoma, small B lymphocytic, NOS	16	4.2	10	3.4
	9690	Follicular lymphoma, NOS	16	4.2	9	3.1
	9691	Follicular lymphoma, grade 2	13	3.4	10	3.4
	9702	Mature T-cell lymphoma, NOS	17	4.4	4	1.4
	9687	Burkitt lymphoma, NOS	11	2.9	6	2.1
	9714	Anaplastic large cell lymphoma, T cell and Null cell type	13	3.4	3	1.0
	9698	Follicular lymphoma, grade 3	5	1.3	6	2.1
	9695	Follicular lymphoma, grade 1	8	2.1	2	0.7
	97193	NK/T-cell lymphoma, nasal and nasal-type	7	1.8	1	0.3
	9729	Precursor T-cell lymphoblastic lymphoma	5	1.3	3	1.0
		Others	27	7.0	12	4.1
Leukemia	9861	Acute myeloid leukemia, NOS	42	18.5	43	20.9
	9863	Chronic myeloid leukemia, NOS	37	16.3	48	23.3
	9823	B-cell chronic lymphocytic leukemia/small lymphocytic lymphom	37	16.3	13	6.3
	9836	Precursor B-cell lymphoblastic leukemia	28	12.3	20	9.7
	9866	Acute promyelocytic leukemia, t(15;17)(q22;q11-12)	7	3.1	14	6.8
	9835	Precursor cell lymphoblastic leukemia, NOS	10	4.4	7	3.4
	9867	Acute monocytic leukemia	6	2.6	9	4.4
	9837	Precursor T-cell lymphoblastic leukemia	9	4.0	6	2.9
	9873	Acute myeloid leukemia with maturation	6	2.6	8	3.9
	9875	Chronic myelogenous leukemia, BCR/ABL positive	6	2.6	7	3.4
	9867	Acute myelomonocytic leukemia	6	2.6	5	2.4
	9801	Acute leukemia, NOS	7	3.1	3	1.5

Table 2.4.3 Number and Percentage of Morphological Types for the Most Common Types of Cancer among Saudi Adult, 2011

Table 2.4.3 Continued

Primary Site	Code	Morphology	Male	%	Female	%
Leukemia Continued	9800	Leukemia, NOS	1	0.4	6	2.9
	9945	Chronic myelomonocytic leukemia, NOS	3	1.3	2	1.0
	9873	Acute myeloid leukemia without maturation	2	0.9	2	1.0
		Others	20	8.8	13	6.3
Liver	8170	Hepatocellular carcinoma, NOS	266	83.1	112	74.2
	8160	Cholangiocarcinoma	20	6.3	15	9.9
	8000	Neoplasm, malignant	16	5.0	8	5.3
	8140	Adenocarcinoma, NOS	10	3.1	5	3.3
	8010	Carcinoma, NOS	1	0.3	3	2.0
	8180	Combined hepatocellular carcinoma and cholangiocarcinoma	2	0.6	2	1.3
	Others	5	1.6	6	4.0	
Lung	8140	Adenocarcinoma, NOS	104	30.4	44	40.7
	8070	Squamous cell carcinoma, NOS	62	18.1	11	10.2
	8041	Small cell carcinoma, NOS	34	9.9	6	5.6
	8046	Non-small cell carcinoma	32	9.4	7	6.5
	8000	Neoplasm, malignant	19	5.6	6	5.6
	8250	Bronchiolo-alveolar adenocarcinoma, NOS	11	3.2	10	9.3
	8010	Carcinoma, NOS	14	4.1	7	6.5
	8012	Large cell carcinoma, NOS	8	2.3	1	0.9
	8071	Squamous cell carcinoma, keratinizing, NOS	8	2.3	0	0.0
	8240	Carcinoid tumor, NOS	3	0.9	4	3.7
	8020	Carcinoma, undifferentiated, NOS	7	2.0	0	0.0
		Others	40	11.7	12	11.1
	Skin	8090	Basal cell carcinoma, NOS	95	45.7	54
8070		Squamous cell carcinoma, NOS	51	24.5	26	21.0
8097		Basal cell carcinoma, nodular	16	7.7	9	7.3
8832		Dermatofibrosarcoma, NOS	8	3.8	14	11.3
8071		Squamous cell carcinoma, keratinizing, NOS	6	2.9	5	4.0
8092		Infiltrating basal cell carcinoma, NOS	5	2.4	5	4.0
8094		Basosquamous carcinoma	2	1.0	4	3.2
		Others	25	12.0	7	5.6
Corpus Uteri	8380	Endometrioid adenocarcinoma, NOS	-	-	190	59.7
	8140	Adenocarcinoma, NOS	-	-	40	12.6
	8980	Carcinosarcoma, NOS	-	-	15	4.7
	8460	Papillary serous cystadenocarcinoma	-	-	10	3.1
	8310	Clear cell adenocarcinoma, NOS	-	-	8	2.5
	8950	Mullerian mixed tumor	-	-	7	2.2
	8010	Carcinoma, NOS	-	-	6	1.9
	8441	Serous cystadenocarcinoma, NOS	-	-	6	1.9
	8930	Endometrial stromal sarcoma, NOS	-	-	5	1.6
	8000	Neoplasm, malignant	-	-	4	1.3
	8560	Adenosquamous carcinoma	-	-	3	.9
	8890	Leiomyosarcoma, NOS	-	-	3	.9
	8323	Mixed cell adenocarcinoma	-	-	3	.9
	8461	Serous surface papillary carcinoma	-	-	3	.9
		Others	-	-	15	4.7
Prostate	8140	Adenocarcinoma, NOS	269	86.8	-	-
	8000	Neoplasm, malignant	18	5.8	-	-
	8550	Acinar cell carcinoma	11	3.5	-	-
	8010	Carcinoma, NOS	11	3.5	-	-
	8001	Tumor cells, malignant	1	.3	-	-

Childhood Cancers in Saudi Arabia, 2011 (≤ 14 years)

The total incident cases reported among children (0-14 years) between January and December 2011 were 817. This represents 5.5% of the total number of cancers in Saudi Arabia. The reported incidents show that cancer was more common among boys than girls, 436 (53.4%) cases were reported among boys and 381 (46.6%) among girls, with a male to female ratio of 114:100. Of all the cases reported there were 686 Saudis, 131 non-Saudis and 0 of “unknown nationality”. Based on Table 2.5.1, the total number of cases analyzed was 789 including 675 (46.4%) Saudis and 123 (15.6%) for non-Saudis. Among Saudis, 363 (53.8%) were male and 312 (46.2%) were female. The male to female ratio among Saudis was 116:100.

Childhood cancers accounted for 6.2% of all cancer among Saudis. The leading cancer among Saudi children was leukemia, which accounted for 39.1 %, followed by Brain, CNS 10.4% then NHL 9.9 % then Hodgkin Disease 6.5% and Bone 6.1% Table 2.5.2. Figure 2.7 shows the top ten sites by sex and frequency, and Table 2.5.3 shows the number and proportion of the morphological types for the most common types of cancer.

	Saudis			Non-Saudis			All
	Male	Female	Total	Male	Female	Total	Total
Analyzed *	363	312	675	65	58	123	789
Invasive	370	315	685	66	58	124	800
In Situ	0	1	1	0	0	0	1
ICD-10 **	7	3	10	1	0	1	11
Total	370	316	686	66	65	131	817

Table 2.5.1 Distribution of Reported Childhood Cancer in Saudi Arabia by Nationality and Sex, 2011

Cancer	No.	%
Leukemia	264	39.1
Brain, CNS	70	10.4
Hodgkin disease	67	9.9
NHL	44	6.5
Kidney	41	6.1
Bone	40	5.9
Eye	35	5.2
Adrenal gland	29	4.3
Connective, Soft tissue	17	2.5
Liver	12	1.8

Table 2.5.2 Ten Most Common Cancers among Saudi Arabia Children, 2011

* Unknown nationalities, in situ cases and ICD-10 conversion failures are excluded from analysis

** ICD-10 conversion failure




Figure 2.7 Ten Most Common Cancer among Saudi Children by sex, 2011

Primary Site	Code	Morphology	Male	%	Female	%
Leukemia	9836	Precursor B-cell lymphoblastic leukemia	70	50.4	62	49.6
	9835	Precursor cell lymphoblastic leukemia, NOS	26	18.7	25	20.0
	9861	Acute myeloid leukemia, NOS	5	3.6	9	7.2
	9837	Precursor T-cell lymphoblastic leukemia	11	7.9	3	2.4
	9801	Acute leukemia, NOS	6	4.3	1	0.8
	9867	Acute monocytic leukemia	2	1.4	5	4.0
	9874	Acute myeloid leukemia with maturation	2	1.4	4	3.2
	9866	Acute promyelocytic leukemia, t(15;17)(q22;q11-12)	4	2.9	2	1.6
	9863	Chronic myeloid leukemia, NOS	3	2.2	1	0.8
	9910	Acute megakaryoblastic leukemia	2	1.4	1	0.8
	9873	Acute myeloid leukemia without maturation	1	0.7	2	1.6
	9826	Burkitt cell leukemia	1	0.7	2	1.6
	9946	Juvenile myelomonocytic leukemia	1	0.7	2	1.6
	9805	Acute biphenotypic leukemia	0	0.0	2	1.6
		Others	5	3.6	4	3.2
Brain, CNS	9470	Medulloblastoma, NOS	10	27.0	10	30.3
	9380	Glioma, malignant	7	18.9	5	15.2
	9392	Ependymoma, anaplastic	5	13.5	2	6.1
	9508	Atypical teratoid/rhabdoid tumor	2	5.4	3	9.1
	9440	Glioblastoma, NOS	0	0.0	4	12.1
	9391	Ependymoma, NOS	3	8.1	0	0.0
	9382	Mixed glioma	3	8.1	0	0.0
	9473	Primitive neuroectodermal tumor, NOS	2	5.4	1	3.0
	9400	Astrocytoma, NOS	0	0.0	2	6.1
	9471	Desmoplastic nodular medulloblastoma	1	2.7	1	3.0
	9401	Astrocytoma, anaplastic	1	2.7	0	0.0
		Choroid plexus carcinoma	1	2.7	0	0.0
		Others	2	5.4	5	15.2

Table 2.5.3 Number and Percentage of Morphological Types for the Most Common Types of Cancer among Saudi Children, 2011.

Table 2.5.3 Continued

Primary Site	Code	Morphology	Male	%	Female	%
NHL	9687	Burkitt lymphoma, NOS	20	42.6	10	50.0
	9590	Malignant lymphoma, NOS	5	10.6	2	10.0
	9729	Precursor T-cell Lymphoblastic Lymphoma	5	10.6	1	5.0
	9750	Malignant histiocytosis	4	8.5	1	5.0
	9680	Malignant Lymphoma, Large B-cell, Diffuse, NOS	3	6.4	0	0.0
	9591	Malignant Lymphoma, Non-Hodgkin, NOS	1	2.1	2	10.0
	9700	Mycosis fungoides	2	4.3	1	5.0
	9727	Precursor cell lymphoblastic lymphoma, NOS	3	6.4	0	0.0
		Others	4	8.5	3	15.0
Hodgkin Disease	9663	Hodgkin lymphoma, nodular sclerosis, NOS	10	40.0	9	47.4
	9652	Hodgkin lymphoma, mixed cellularity, NOS	9	36.0	3	15.8
	9650	Hodgkin lymphoma, NOS	2	8.0	6	31.6
	9659	Hodgkin lymphoma, nodular lymphocyte predominance	3	12.0	0	0.0
	9651	Hodgkin lymphoma, lymphocyte-rich	1	4.0	1	5.3
		All	25	100.0	19	100.0
Connective Tissue	9500	Neuroblastoma, NOS	5	31.3	3	21.4
	8910	Embryonal rhabdomyosarcoma, NOS	2	12.5	4	28.6
	9581	Alveolar soft part sarcoma	1	6.3	1	7.1
	8963	Malignant rhabdoid tumor	2	12.5	0	0.0
	9364	Peripheral neuroectodermal tumor	1	6.3	1	7.1
	8900	Rhabdomyosarcoma, NOS	0	0.0	2	14.3
			Others	5	31.3	3
Bone	9181	Ewing sarcoma	8	44.4	10	43.5
	9370	Osteosarcoma, NOS	6	33.3	5	21.7
	9260	Chondroblastic osteosarcoma	4	22.2	3	13.0
	8000	Peripheral neuroectodermal tumor	0	0.0	2	8.7
	9180	Chordoma, NOS	0	0.0	1	4.3
	9364	Neoplasm, malignant	0	0.0	1	4.3
	9071	Yolk sac tumor	0	0.0	1	4.3
			All	18	100	23
Kidney	8960	Nephroblastoma, NOS	13	86.7	17	85.0
	8964	Clear cell sarcoma of kidney	1	6.7	1	5.0
	9508	Atypical teratoid/rhabdoid tumor	0	0.0	1	5.0
	8963	Malignant rhabdoid tumor	1	6.7	0	0.0
	8312	Renal cell carcinoma, NOS	0	0.0	1	5.0
			All	15	100.0	20
Eye	9510	Retinoblastoma, NOS	8	57.1	10	67
	9512	Retinoblastoma, undifferentiated	5	35.7	4	27
	8910	Embryonal rhabdomyosarcoma, NOS	1	7.1	1	7
Liver	8970	Hepatoblastoma	7	70.0	6	85.7
	8171	Hepatocellular carcinoma, fibrolamellar	1	10.0	0	0.0
	8170	Hepatocellular carcinoma, NOS	1	10.0	0	0.0
	8982	Malignant myoepithelioma	1	10.0	0	0.0
	8000	Neoplasm, malignant	0	0.0	1	14.3
Adrenal Gland	9500	Neuroblastoma, NOS	10	100.0	2	100.0

International Comparison of Age-Standardized Incidence Rates

Worldwide, GLOBOCAN, 2012 estimated that 14,090,149 people developed cancer in 2012. Of these, 80,142,73 (56.9%) were in developing countries and 60,758,76 (43.1%) in developed countries. In men, ASR is high in Northern America, Europe, and Australia\New Zealand while the lowest ASR is in Western/ Middle Africa and South-Central Asia. As in males, the regions with the highest ASR in females are Northern America, Europe, and Australia\New Zealand while the lowest ASR in Middle/Northern/Western Africa and in South-Eastern Asia and South-Central Asia. According to 2012 estimates, the most common cancer site worldwide among men was lung cancer, followed by prostate, colorectal, stomach then liver. However in developed countries prostate was the leading cancer followed by lung, colorectal, then bladder followed by stomach, while in developing countries lung cancer was first followed by liver, stomach, prostate and NHL cancers. In women, the most common cancer site was breast followed by colorectal, lung, cervix uteri cancers and corpus uteri. In developing countries among women, breast cancer was the most common followed by cervix uteri, lung, then colorectal, and stomach. While in the developed countries breast cancer was the leading cancer followed by cancers of the colorectal, corpus uteri then Hodgkin disease.




Figure 2.9.1 Comparison of ASR* for Saudi Males with Selected Countries**




Figure 2.9.2 Comparison of ASR* for Saudi Female with Selected Countries**

* ASR Rer 100.000

** Source for this information is summarized on Page 66

PART III
CANCER INCIDENCE
FOR MOST COMMON SITES 2011



Cancer Incidence for Most Common Sites, 2011

In this section, the incidence of the most common cancers among Saudi males and females are outlined in accordance to their relative frequencies. The relevant data incorporate details for all patients presented over the period of January through December 2011.

Site	Male	Female	All	%
Breast	16	1590	1606	14.8
Colorectal	657	537	1194	11.0
Thyroid	154	646	800	7.4
Non-Hodgkin Lymphoma	432	312	744	6.8
Leukemia	366	331	697	6.4
Liver	330	158	488	4.5
Trachea, Bronchus, Lung	343	109	452	4.2
Hodgkin Disease	184	157	341	3.1
Other Skin	208	125	333	3.1
Corpus Uteri	0	318	318	2.9
Prostate	311	0	311	2.9
Stomach	162	133	295	2.7
Kidney	178	112	290	2.7
Brain	170	99	269	2.5
Bladder	180	52	232	2.1
Other sites	1222	1277	2499	23.0
All Sites	4913	5956	10869	100.0

Table 3.1 Most Common Cancers among Saudis by Sex, 2011

Female Breast Cancer (C50)

There were 1590 female breast cancer cases for year 2011. Breast cancer ranked first among females accounting for 26.6% of all newly diagnosed female cancers (5,956) in year 2011. The ASR was 23.4/100,000 for female population. The median age at diagnosis was 48 years (Range 19-109 years)




Figure 3.1.1 Age-Specific Incidence Rate (AIR) for Female Cancer in Saudi Arabia, 2011

ICD 3 - 0	Morphology	Female	%
8500	Infiltrating Duct Carcinoma, NOS	1218	76.5
8520	Lobular carcinoma, NOS	88	5.5
8010	Carcinoma, NOS	56	3.5
8000	Neoplasm, malignant	53	3.3
8522	Infiltrating duct and lobular carcinoma	41	2.6
8523	Infiltrating duct mixed with other types of carcinoma	23	1.4
8510	Medullary carcinoma, NOS	19	1.2
8480	Mucinous adenocarcinoma	13	0.8
9020	Phyllodes tumor, malignant	12	0.8
	Others	69	4.3

Table 3.1.1 Morphological Distribution of Female Breast Cancer in Saudi Arabia, 2011




Figure 3.1.2 Stage Distribution of Female Breast Cancer in Saudi Arabia, 2011




Figure 3.1.4 Comparison of ASR* for Female Breast Cancer among Saudi Females with ASR in Selected Countries**

* ASR Per 100,000

** Source for this information is summarized on page 66

Colorectal (C18-C20)

There were 1,194 cases of colorectal cancer accounting for 11.0% of all newly diagnosed cases in year 2011. This cancer ranked first among male and third among female. It affected 657 (55.0%) males and 537 (45.0 %) females with a male to female ratio of 122:100. The ASR males was 11.3/100,000 and for females 9.0/100,000. The median age at diagnosis was 59 years among males (range 11-96 years) and 56 years among females (range 19-106 years).




Figure 3.2.1 Age-Specific Incidence Rate (AIR) for Colorectal Cancer in Saudi Arabia, 2011

ICD 3 - 0	Morphology	Male	%	Female	%
8140	Adenocarcinoma, NOS	520	79.1	421	78.4
8480	Mucinous adenocarcinoma	43	6.5	38	7.1
8263	Adenocarcinoma in tubulovillous adenoma	14	2.1	16	3.0
8000	Neoplasm, malignant	14	2.1	10	1.9
8261	Adenocarcinoma in villous adenoma	11	1.7	12	2.2
8210	Adenocarcinoma in adenomatous polyp	15	2.3	6	1.1
8490	Signet ring cell carcinoma	10	1.5	8	1.5
8010	Carcinoma, NOS	7	1.1	7	1.3
8481	Mucin-producing adenocarcinoma	5	0.8	5	0.9
	Others	18	2.7	14	2.6

Table 3.2.1 Morphological Distribution of Colorectal Cancer in Saudi Arabia, 2011




Figure 3.2.2 Stage Distribution of Colorectal Cancer in Saudi Arabia, 2011




Figure 3.2.4 Comparison of ASR* for Colorectal Cancer among Saudi with ASR in Selected countries**

*ASR Per 100,000

** Source for this information is summarized on page 66

Thyroid (C73)

There were 800 cases of thyroid cancer accounting for 7.4% of all newly diagnosed cases for the year 2011. This cancer ranked second among female and thirteenth among male population. It affected 154 (19.2%) males and 646 (80.8%) females with a female to male ratio of 419:100. The ASR was 2.2/100,000 for male and 8.1 /100,000 for females. The median age at diagnosis was 46 years among males (range 11-90 years) and 41 years among females (range 11-99 years).




Figure 3.3.1 Age-Specific Incidence Rate (AIR) for Thyroid Cancer in Saudi Arabia, 2011

ICD 3 - 0	Morphology	Male	%	Female	%
8260	Papillary adenocarcinoma, NOS	76	49.4	315	48.7
8340	Papillary carcinoma, follicular variant	16	10.4	115	17.8
8341	Papillary microcarcinoma	8	5.2	73	11.3
8344	Papillary carcinoma, columnar cell	7	4.5	38	5.9
8343	Papillary carcinoma, encapsulated	7	4.5	28	4.3
8330	Follicular adenocarcinoma, NOS	9	5.8	13	2.0
8290	Oxyphilic adenocarcinoma	3	1.9	13	2.0
8335	Follicular carcinoma, minimally invasive	4	2.6	11	1.7
8510	Medullary carcinoma, NOS	5	3.2	8	1.2
8050	Papillary carcinoma, NOS	2	1.3	11	1.7
8021	Carcinoma, anaplastic, NOS	5	3.2	7	1.1
	Others	12	7.8	15	2.3

Table 3.3.1 Morphological Distribution of Thyroid Cancer in Saudi Arabia, 2011




Figure 3.3.2 Stage Distribution of Thyroid Cancer in Saudi Arabia, 2011




Figure 3.3.4 Comparison of ASR* for Thyroid Cancer among Saudi with ASR in Selected countries**

*ASR Per 100,000

** Source for this information is summarized on page 66

Non-Hodgkin Lymphoma (C82-C85: C96)

There were 744 cases of Non-Hodgkin Lymphoma accounting for 6.8 % of all newly diagnosed cancers in year 2011. This cancer ranked second among male and sixth among female. It affected 432 (58.1%) males and 312 (41.9%) females with a male to female ratio of 138:100. The ASR for males was 6.4/100,000 and 4.8/100,000 for females. The median age at diagnosis was 54 years among males (range 0-110 years) and 52 years among females (range 0-102 years)




Figure 3.4.1 Age-Specific Incidence Rate (AIR) for NHL in Saudi Arabia, 2011

ICD 3 - 0	Morphology	Male	%	Female	%
9680	Malignant lymphoma, large B-cell, diffuse, NOS	185	42.8	158	50.6
9687	Burkitt lymphoma, NOS	31	7.2	16	5.1
9590	Malignant lymphoma, NOS	24	5.6	17	5.4
9591	Malignant lymphoma, non-Hodgkin, NOS	16	3.7	22	7.1
9700	Mycosis fungoides	18	4.2	19	6.1
9699	Marginal zone B-cell lymphoma, NOS	15	3.5	16	5.1
9670	Malignant lymphoma, small B lymphocytic, NOS	16	3.7	10	3.2
9690	Follicular lymphoma, NOS	16	3.7	9	2.9
9691	Follicular lymphoma, grade 2	14	3.2	10	3.2
9702	Mature T-cell lymphoma, NOS	17	3.9	5	1.6
	Others	80	18.5	30	9.6

Table 3.4.1 Morphological Distribution of NHL in Saudi Arabia, 2011




Figure 3.4.2 Stage Distribution of NHL in Saudi Arabia, 2011




Figure 3.4.4 Comparison of ASR* for NHL among Saudi with ASR in Selected Countries**

*ASR Per 100,000

** Source for this information is summarized on page 66

Leukemia (C91 - C95)

There were 697 cases of leukemia accounting for 6.4% of all newly diagnosed cancers in year 2011. This cancer ranked third for males and the fourth for females. It affected 366 (52.2%) males and 331 (47.5%) females with a male to female ratio of 110:100. The ASR in males was 4.5/100,000 and 4.0/100,000 for females. The median age at diagnosis is 23 years among males (range 0-95 years) and 26 years among females (range 0-95 years).




Figure 3.5.1 Age-Specific Incidence Rate (AIR) for Leukemia in Saudi Arabia, 2011

ICD 3 - 0	Morphology	Male	%	Female	%
9836	Precursor B-cell lymphoblastic leukemia	98	26.8	82	24.8
9861	Acute myeloid leukemia, NOS	47	12.8	52	15.7
9863	Chronic myeloid leukemia, NOS	40	10.9	49	14.8
9835	Precursor cell lymphoblastic leukemia, NOS	36	9.8	32	9.7
9823	B-cell chronic lymphocytic leukemia/small lymphocytic lymphom	37	10.1	13	3.9
9837	Precursor T-cell lymphoblastic leukemia	20	5.5	9	2.7
9866	Acute promyelocytic leukemia, t(15;17)(q22;q11-12)	11	3.0	16	4.8
9891	Acute monocytic leukemia	8	2.2	14	4.2
9874	Acute myeloid leukemia with maturation	8	2.2	12	3.6
9801	Acute leukemia, NOS	13	3.6	4	1.2
9875	Chronic myelogenous leukemia, BCR/ABL positive	6	1.6	7	2.1
9867	Acute myelomonocytic leukemia	7	1.9	5	1.5
9800	Leukemia, NOS	2	0.5	7	2.1
9873	Acute myeloid leukemia without maturation	3	0.8	4	1.2
9826	Burkitt cell leukemia	1	0.3	4	1.2
	Others	29	7.9	21	6.3

Table 3.5.1 Morphological Distribution of Leukemia in Saudi Arabia, 2011




Figure 3.5.3 Comparison of ASR* for Leukemia among Saudi with ASR in Selected Countries**

*ASR Per 100,000

** Source for this information is summarized on page 66

Liver (C22)

There were 488 cases of liver cancer accounting for 4.5% of all newly diagnosed cases in year 2011. This cancer ranked fifth in males and seventh in females. It affected 330 (67.6 %) males and 158 (32.4%) females with a male to female ratio of 208:100. The ASR was 6.1/100,000 for males and 2.9/100,000 for females. The median age at diagnosis was 68 years in males (range 0-98 years) and 64 years in females (range 0-109 years).




Figure 3.6.1 Age-Specific Incidence Rate (AIR) for Liver Cancer in Saudi Arabia, 2011

ICD 3 - 0	Morphology	Male	%	Female	%
8170	Hepatocellular carcinoma, NOS	267	80.9	112	70.9
8000	Cholangiocarcinoma	20	6.1	15	9.5
8610	Neoplasm, malignant	16	4.8	9	5.7
8140	Adenocarcinoma, NOS	10	3.0	5	3.2
8970	Hepatoblastoma	7	2.1	6	3.8
8010	Carcinoma, NOS	1	0.3	3	1.9
	Others	9	2.7	8	5.1

Table 3.6.1 Morphological Distribution of Liver in Saudi Arabia, 2011




Figure 3.6.2 Stage Distribution of Liver Cancer in Saudi Arabia, 2011




Figure 3.6.4 Comparison of ASR* for Liver among Saudi with ASR in Selected Countries**

*ASR Per 100,000

** Source for this information is summarized on page 66

Lung (C33 - C34)

There were 452 cases of lung cancer accounting for 4.2% of all diagnosed cases in year 2011. Lung cancer ranked fourth among male and twelfth among female. It affected 343 (75.9%) males and 109 (24.1%) females with a male to female ratio of 314:100. The ASR was 6.4/100,000 for males and 1.9/100,000 for females. The median age at diagnosis was 68 years among males (range 11-104 years) and 60 years among females (range 13-94 years).




Figure 3.7.1 Age-Specific Incidence Rate (AIR) for Lung Cancer in Saudi Arabia, 2011

ICD 3 - 0	Morphology	Male	%	Female	%
8140	Adenocarcinoma, NOS	104	30.3	44	40.4
8070	Squamous cell carcinoma, NOS	62	18.1	11	10.1
8041	Small cell carcinoma, NOS	34	9.9	6	5.5
8046	Non-small cell carcinoma	32	9.3	7	6.4
8000	Neoplasm, malignant	19	5.5	6	5.5
8250	Bronchiolo-alveolar adenocarcinoma, NOS	11	3.2	10	9.2
8010	Carcinoma, NOS	14	4.1	7	6.4
8012	Large cell carcinoma, NOS	8	2.3	1	0.9
8071	Squamous cell carcinoma, keratinizing, NOS	8	2.3	0	0.0
8240	Carcinoid tumor, NOS	3	0.9	4	3.7
	Others	48	14.0	13	11.9

Table 3.7.1 Morphological Distribution of Lung in Saudi Arabia, 2011




Figure 3.7.2 Stage Distribution of Lung Cancer in Saudi Arabia, 2011




Figure 3.7.4 Comparison of ASR* for Lung Cancer among Saudi with ASR in Selected Countries**

*ASR Per 100,000

** Source for this information is summarized on page 66

Hodgkin Disease (C 81)

There were 341 cases of Hodgkin disease accounting for 3.1% of all newly diagnosed cases in year 2011. Hodgkin disease ranked eighth among both males and females. It affected 184 (54.0%) males and 157 (46.0%) females with a male to female ratio of 117:100. The ASR was 1.9/100,000 for males and 1.7/100,000 for females. The median age at diagnosis was 25 years (range 0-90 years) in males and 24 year in females (range 0-89).




Figure 3.8.1 Age-Specific Incidence Rate (AIR) for Hodgkin Disease in Saudi Arabia, 2011

ICD 3 - 0	Morphology	Male	%	Female	%
9663	Hodgkin lymphoma, nodular sclerosis, NOS	92	50.0	81	51.6
9650	Hodgkin lymphoma, NOS	25	13.6	26	16.6
9652	Hodgkin lymphoma, mixed cellularity, NOS	28	15.2	20	12.7
9651	Hodgkin lymphoma, lymphocyte-rich	10	5.4	11	7.0
9659	Hodgkin lymphoma, nodular lymphocyte predominance	16	8.7	5	3.2
9653	Hodgkin lymphoma, lymphocyte depletion, NOS	3	1.6	4	2.5
9665	Hodgkin lymphoma, nodular sclerosis, grade 1	4	2.2	3	1.9
9667	Hodgkin lymphoma, nodular sclerosis, grade 2	5	2.7	2	1.3
9664	Hodgkin lymphoma, nodular sclerosis, cellular phase	1	0.5	3	1.9
9654	Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis	0	0.0	1	0.6
9655	Hodgkin lymphoma, lymphocyte depletion, reticular	0	0.0	1	0.6

Table 3.8.1 Morphological Distribution of Hodgkin Disease in Saudi Arabia, 2011




Figure 3.8.2 Stage Distribution of Hodgkin Disease in Saudi Arabia, 2011




Figure 3.8.4 Comparison of ASR* for Hodgkin Disease among Saudi with ASR in Selected Countries**

*ASR Per 100,000

** Source for this information is summarized on page 66

Skin (Non-Melanoma) (C 44)

There were 333 cases of skin cancer accounting for 3.1% of all newly diagnosed cases in year 2011. This cancer ranked seventh for males tenth females. It affected 208 (62.5%) males and 125 (37.5%) females with a male to female ratio of 166:100. The ASR was 3.6/100,000 for males and 2.2/100,000 for females. The median age at diagnosis was 70 years among males (range 20-120 years) and 63 years among females (range 10-99years).




Figure 3.9.1 Age-Specific Incidence Rate (AIR) for Skin Cancer in Saudi Arabia, 2011

ICD 3 - 0	Morphology	Male	%	Female	%
8090	Basal cell carcinoma, NOS	95	45.9	54	43.2
8070	Squamous cell carcinoma, NOS	51	24.6	26	20.8
8097	Basal cell carcinoma, nodular	16	7.7	9	7.2
8832	Dermatofibrosarcoma, NOS	8	3.9	15	12.0
8071	Squamous cell carcinoma, keratinizing, NOS	6	2.9	5	4.0
8092	Infiltrating basal cell carcinoma, NOS	5	2.4	5	4.0
8094	Basosquamous carcinoma	2	1.0	4	3.2
8091	Multifocal superficial basal cell carcinoma	5	2.4	1	0.8
8410	Sebaceous adenocarcinoma	5	2.4	1	0.8
8098	Adenoid basal carcinoma	1	0.5	1	0.8
	Others	13	6.3	4	3.2

Table 3.9.1 Morphological Distribution of Skin Cancer in Saudi Arabia, 2011




Figure 3.9.2 Stage Distribution of Skin Cancer in Saudi Arabia, 2011




Figure 3.9.4 Comparison of ASR* for Skin Cancer among Saudi with ASR in Selected Countries**

*ASR Per 100,000

** Source for this information is summarized on page 66

Corpus Uteri (C 54)

There were 318 cases of corpus uteri cancer among females accounting for 2.9% of all newly diagnosed cases for females (5,956) in year 2011. This cancer ranked fifth among female, with ASR was 5.8/100,000 in females. The median age at diagnosis was 61 years (range 20-98 years).




Figure 3.10.1 Age-Specific Incidence Rate (AIR) for Corpus Uteri in Saudi Arabia, 2011

ICD 3 - 0	Morphology	Female	%
8380	Endometrioid adenocarcinoma, NOS	190	59.7
8140	Adenocarcinoma, NOS	40	12.6
8980	Carcinosarcoma, NOS	15	4.7
4860	Papillary serous cystadenocarcinoma	10	3.1
8310	Clear cell adenocarcinoma, NOS	8	2.5
8950	Mullerian mixed tumor	7	2.2
8010	Carcinoma, NOS	6	1.9
8441	Serous cystadenocarcinoma, NOS	6	1.9
8930	Endometrial stromal sarcoma, NOS	5	1.6
8000	Neoplasm, malignant	4	1.3
	Others	27	8.5

Table 3.10.1 Morphological Distribution of Coups Uteri Cancer in Saudi Arabia, 2011




Figure 3.10.2 Stage Distribution of Corpus Uteri Cancer in Saudi Arabia, 2011




Figure 3.10.4 Comparison of ASR* for Corpus Uteri among Saudi with ASR in Selected Countries**

*ASR Per 100,000

** Source for this information is summarized on page 66

Prostate (C61)

There were 311 cases of prostate cancer accounting for 2.9% of all newly diagnosed cases among males in year 2011. This cancer ranked sixth among males. The ASR was 6.0/100,000 among male population. The median age at diagnosis was 72 years (range 6-101 years).




Figure 3.11.1 Age-Specific Incidence Rate (AIR) for Prostate Cancer in Saudi Arabia, 2011

ICD 3 - 0	Morphology	Male	%
8140	Adenocarcinoma, NOS	269	86.5
8000	Neoplasm, malignant	18	5.8
8550	Acinar cell carcinoma	11	3.5
8010	Carcinoma, NOS	11	3.5
8910	Embryonal rhabdomyosarcoma, NOS	1	0.3
8001	Tumor cells, malignant	1	0.3

Table 3.11.1 Morphological Distribution of Prostate Cancer in Saudi Arabia, 2011




Figure 3.11.2 Stage Distribution of Prostate Cancer in Saudi Arabia, 2011




Figure 3.11.4 Comparison of ASR* for Prostate among Saudi with ASR in Selected Countries**

*ASR Per 100,000

** Source for this information is summarized on page 66

Stomach (C16)

There were 295 cases of stomach cancer accounting for 2.7% of all newly diagnosed cases in year 2011. This cancer ranked twelfth among males and ninth among females. It affected 162 (54.9%) males and 133 (45.1%) females with a male to female ratio of 121:100. The ASR for male was 4.3/100,000 and 3.0/100,000 for females. The median age at diagnosis was 64 years among males (range 23-107 years) and 63 years among females (range 17-100 years).




Figure 3.12.1 Age-Specific Incidence Rate (AIR) for Stomach Cancer in Saudi Arabia, 2011

ICD O	Morphology	Male	%	Female	%
8140	Adenocarcinoma, NOS	79	48.5	47	35.3
8490	Signet ring cell carcinoma	33	20.2	31	23.3
8144	Adenocarcinoma, intestinal type	19	11.7	12	9.0
8000	Neoplasm, malignant	6	3.7	8	6.0
8145	Carcinoma, diffuse type	3	1.8	8	6.0
8936	Gastrointestinal stromal sarcoma	4	2.5	5	3.8
8480	Mucinous adenocarcinoma	5	3.1	3	2.3
8010	Carcinoma, NOS	3	1.8	4	3.0
8246	Neuroendocrine carcinoma, NOS	4	2.5	2	1.5
8070	Squamous cell carcinoma, NOS	1	0.6	3	2.3
	Others	6	3.7	10	7.5

Table 3.12.1 Morphological Distribution of Stomach Cancer in Saudi Arabia, 2011




Figure 3.12.2 Stage Distribution of Stomach Cancer in Saudi Arabia, 2011




Figure 3.12.4 Comparison of ASR* for Stomach among Saudi with ASR in Selected Countries**

*ASR Per 100,000

** Source for this information is summarized on page 66

Kidney (C64)

There were 290 cases of Kidney cancer accounting for 2.7% of all newly diagnosed cases in year 2011. This cancer ranked tenth among male and eleventh among female. It affected 178 (61.3%) males and 112 (38.6%) females with a male to female ratio of 159:100. The ASR was 2.9/100,000 for male and 1.7/100,000 for females. The median age at diagnosis was 57 years among males (range 0-94 years) and 53 years among females (range 0 - 96 Years)




Figure 3.13.1 Age-Specific Incidence Rate (AIR) for Kidney Cancer in Saudi Arabia, 2011

ICD - 3 - 0	Morphology	Male	%	Female	%
8312	Renal cell carcinoma, NOS	93	52.2	57	50.9
8960	Nephroblastoma, NOS	13	7.3	18	16.1
8310	Clear cell adenocarcinoma, NOS	17	9.6	11	9.8
8317	Renal cell carcinoma, chromophobe type	15	8.4	7	6.3
8260	Papillary adenocarcinoma, NOS	16	9.0	5	4.5
8318	Renal cell carcinoma, sarcomatoid	4	2.2	6	5.4
8000	Neoplasm, malignant	3	1.7	2	1.8
8316	Cyst-associated renal cell carcinoma	3	1.7	1	0.9
8120	Transitional cell carcinoma, NOS	4	2.2	0	0.0
8010	Carcinoma, NOS	2	1.1	0	0.0
	Others	8	4.5	5	4.5

Table 3.13.1 Morphological Distribution of Kidney Cancer in Saudi Arabia, 2011




Figure 3.13.2 Stage Distribution of Kidney Cancer in Saudi Arabia, 2011




Figure 3.13.4 Comparison of ASR* for Kidney among Saudi with ASR in Selected Countries**

*ASR Per 100,000

** Source for this information is summarized on page 66

Brain (C70-C72)

There were 269 cases of Brain cancer accounting for 2.5% of all newly diagnosed cases in year 2011. This cancer ranked eleventh among male and thirteenth among female. It affected 170 (63.2%) males and 99 (38.8%) females with a male to female ratio of 171:100. The ASR was 2.2/100,000 for male and 1.2/100,000 for females. The median age at diagnosis was 41 years among males (range 0-97 years) and 24 years among females (range 0-81 years).




Figure 3.14.1 Age-Specific Incidence Rate (AIR) for Brain Cancer in Saudi Arabia, 2011

ICD 3 - 0	Morphology	Male	%	Female	%
9440	Glioblastoma, NOS	69	40.6	30	30.3
9470	Medulloblastoma, NOS	14	8.2	15	15.2
9380	Glioma, malignant	10	5.9	11	11.1
8000	Neoplasm, malignant	6	3.5	8	8.1
9400	Astrocytoma, NOS	5	2.9	6	6.1
9382	Mixed glioma	10	5.9	1	1.0
93923	Ependymoma, anaplastic	7	4.1	3	3.0
9450	Oligodendroglioma, NOS	8	4.7	2	2.0
9401	Astrocytoma, anaplastic	6	3.5	3	3.0
9391	Ependymoma, NOS	6	3.5	3	3.0
	Other	29	17.1	17	17.2

Table 3.14.1 Morphological Distribution of Brain Cancer in Saudi Arabia, 2011




Figure 3.14.2 Stage Distribution of Brain Cancer in Saudi Arabia, 2011




Figure 3.14.4 Comparison of ASR* for Brain among Saudi with ASR in Selected Countries**

*ASR Per 100,000

** Source for this information is summarized on page 66

Bladder (C67)

There were 232 cases of Bladder cancer accounting for 2.1% of all newly diagnosed cases in year 2011. This cancer ranked ninth among male and fourteenth among female. It affected 180 (77.6%) males and 52 (22.4%) females with a male to female ratio of 346:100. The ASR was 3.3/100,000 for male and 1.0/100,000 for females. The median age at diagnosis was 65 years among males (range 25-117 years) and 67 years among females (range 1-89 years).




Figure 3.14.1 Age-Specific Incidence Rate (AIR) for Bladder Cancer in Saudi Arabia, 2011

ICD 3 - 0	Morphology	Male	%	Female	%
8130	Papillary transitional cell carcinoma	110	60.4	20	38.5
8120	Transitional cell carcinoma, NOS	46	25.3	16	30.8
8070	Squamous cell carcinoma, NOS	5	2.7	5	9.6
8000	Neoplasm, malignant	3	1.6	6	11.5
8010	Carcinoma, NOS	4	2.2	2	3.8
8071	Squamous cell carcinoma, keratinizing, NOS	4	2.2	1	1.9
8140	Adenocarcinoma, NOS	2	1.1	0	0.0
	Others	8	4.4	2	3.8

Table 3.15.1 Morphological Distribution of Bladder Cancer in Saudi Arabia, 2011




Figure 3.14.2 Stage Distribution of Bladder Cancer in Saudi Arabia, 2011




Figure 3.15.4 Comparison of ASR* for Bladder among Saudi with ASR in Selected Countries**

*ASR Per 100,000

** Source for this information is summarized on page 66

** Sources

1. Canadian Cancer Statistics 2011. Canadian Cancer Society, Statistics Canada, Provincials/Territorial Cancer Registries, Public Health Agency of Canada.
2. Cancer in Ireland 2013: Annual report of the National Cancer Registry. National Cancer Registry Ireland.
3. Cancer Incidence and Mortality in Western Australia, 2010. A Report of the Western Australian Cancer Registry.
4. CDC. Center for Disease Control and Prevention. Department of Health and Human Services. National Program of Cancer Registries (NPCR). 2010 Cancer Types Grouped by Race and Ethnicity. Available from:
<http://apps.nccd.cdc.gov/uscs/cancersbyraceandethnicity.aspx?printfriendly=1>
5. National Cancer Registration and Statistics in Korea. Cancer Incidence in Korea 2010.
6. Cancer in Norway 2011. Cancer incidence, mortality, survival and prevalence in Norway.
7. Singapore Cancer Registry. Interim Annual Registry Report. Trends in Cancer Incidence in Singapore 2006-2010. National Registry of Diseases Office (NRDO). Available from:
https://www.nrdo.gov.sg/uploadedFiles/NRDO/Cancer_Trends_Report_06-10_final2.pdf
8. The Hashemite Kingdom of Jordan Ministry of Health. Non-Communicable Diseases Directorate. Jordan Cancer Registry Cancer Incidence in Jordan 2009. Available from:
<http://www.moh.gov.jo/AR/Documents/Annual%20Incidence%20of%20cancer%20in%20Jordan%202010.pdf>
9. Atlas De Mortalidad Por Cancer. Argentina, 2007-2011.
10. Welsh Cancer Intelligence & Surveillance Unit. Annual Publication No. SA12/01 Cancer Incidence in Wales 2006-2010. Available from:
<http://www.wales.nhs.uk/sites3/Documents/242/incpub2012.pdf>
11. Twelve Years Cancer Incidence among Nationals of the GCC States, 1998-2009.
12. GLOBOCAN 2012, Cancer Incidence and Mortality Worldwide, IARC, Lyon: International Agency for Research on Cancer. Available from:
http://www-dep.iarc.fr/globocan/im_sel.HTM
13. Cancer Incidence in Five Continents Vol. X, IARC. Scientific Publication, Lyon, France, 2013. Available from:
<http://ci5.iarc.fr/CI5-X/ci5-X.htm>

PART IV
CANCER AMONG NON-SAUDIS
2011

Cancer among Non- Saudi Population 2011

Between January and December 2011, a total of 3364 cancer cases were reported among Non-Saudi residents. In Situ cases were 99 and 11 cases were ICD-O-3 coded that failed to convert to ICD-10 codes as described in the data management (see page 12 and page 92). This puts the total number of exclusions from the analysis as 110 cases. As a result, the total number of cases analyzed was 3,353. Out of this 1,690 (50.4%) were males and 1,663 (49.6%) were females. The male to female ratio was 102:100. Taking into consideration the population structure of non-Saudis and the fact that cancer is primarily a disease of the elderly; the pattern of cancer had some significant differences. Those under 15 represented 19.4% of the population, those 60 years and over represented 2.3% and the 15 to 59 age-group represented 78.3% of non-Saudi population. During 2011, approximately 3.7% of all cancers occurred before the age of 15, 21.6 % occurred between the ages 15 to 39 years, 59.9% were between the ages 40-64, and 14.8% occurred after the age of 64. The median age at diagnosis was 52 years in males (range 0-90 years) and 47 years in females (range 0-102 years).

Cancer	No.	%
Breast	671	20.0
Colorectal	377	11.2
NHL	173	5.2
Skin	165	4.9
Thyroid	160	4.8
Leukaemia	153	4.6
Lung	135	4.0
Prostate	122	3.6
Stomach	107	3.2
Bladder	92	2.7
Other Sites	1198	35.7

Table 4.1 Ten most common cancers among Non-Saudis, 2011

Nationality	All		Male		Female	
	No.	%	No.	%	No.	%
Yemen	588	17.5	313	18.5	275	16.5
Egypt	405	12.1	233	13.8	172	10.3
Philippines	329	9.8	126	7.5	203	12.2
Sudan	308	9.2	175	10.4	133	8.0
Pakistan	218	6.5	115	6.8	103	6.2
Syrian Arab Republic	193	5.8	94	5.6	99	6.0
India	153	4.6	96	5.7	57	3.4
Gaza Strip(Palestine)	120	3.6	59	3.5	61	3.7
Indonesia	105	3.1	13	0.8	92	5.5
Jordan	91	2.7	53	3.1	38	2.3
Bangladesh	83	2.5	65	3.8	18	1.1
Somalia	73	2.2	21	1.2	52	3.1
Bahrain	50	1.5	19	1.1	31	1.9
Lebanon	46	1.4	33	2.0	13	0.8
United States of America	46	1.4	34	2.0	12	0.7
United Kingdom	45	1.3	34	2.0	11	0.7
Ethiopia	44	1.3	10	0.6	34	2.0
Eritrea	42	1.3	16	0.9	26	1.6
Nigeria	34	1.0	15	0.9	19	1.1
Chad	30	0.9	9	0.5	21	1.3
Kuwait	29	0.9	7	0.4	22	1.3
Morocco	24	0.7	7	0.4	17	1.0
Myanmar	22	0.7	12	0.7	10	0.6
Sri Lanka	22	0.7	8	0.5	14	0.8
Afghanistan	19	0.6	9	0.5	10	0.6
Canada	18	0.5	4	0.2	14	0.8
Turkey	17	0.5	12	0.7	5	0.3
Iraq	16	0.5	6	0.4	10	0.6
Palestinian	16	0.5	8	0.5	8	0.5
Other Nationalities	166	5.0	83	4.9	83	5.0

Table 4.2 Distribution of cancer cases among different nationalities in order of relative frequency, 2011




Figure 4.1 Ten Most common cancers among Non-Saudi by Sex, 2011




Figure 4.2 age specific incidence rate for all cancers among non- Saudis in Saudi Arabia, 2011

PART V

Incidence Tables

Table 5.1.1 - Number of Cancer Cases Among Saudi Males by Primary Site and Age Groups, 2011

ICD (10th)	Site	All Ages	Age Unk	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Total (%)
C00	Lip	8	0	0	0	0	0	0	1	1	0	1	0	1	0	0	1	0	3	0.2%
C01-C02	Tongue	44	0	0	0	0	0	2	0	1	3	4	8	3	2	3	5	9	4	0.9%
C03-C06	Mouth	41	0	0	1	0	0	0	0	0	4	4	2	2	1	3	6	6	14	0.8%
C07-C08	Salivary glands	14	1	0	0	0	0	0	1	1	1	3	2	2	0	0	1	1	1	0.3%
C09	Tonsil	4	0	0	0	0	1	0	0	0	0	0	0	1	1	0	0	0	0	0.1%
C10	Other Oropharynx	3	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	1	0.1%
C11	Nasopharynx	121	0	0	2	7	0	3	1	5	8	19	14	16	8	12	8	10	8	2.5%
C12-C13	Hypopharynx	9	0	0	0	0	0	0	0	0	0	1	0	0	0	1	1	2	4	0.2%
C14	Pharynx unspec.	3	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0.1%
C15	Oesophagus	76	0	0	0	0	0	0	2	0	5	2	3	4	5	8	4	15	28	1.5%
C16	Stomach	162	0	0	0	0	0	2	2	5	6	5	9	23	15	16	17	25	37	3.3%
C17	Small intestine	35	0	0	0	0	0	1	1	1	2	1	5	6	5	4	2	6	6	0.7%
C18	Colon	378	0	0	1	0	0	0	5	6	20	22	32	58	43	39	59	37	56	7.7%
C19-C20	Rectum	279	0	0	1	0	0	7	6	9	12	23	27	31	31	28	40	26	38	5.7%
C21	Anus	11	0	0	0	0	0	0	0	1	2	2	0	3	1	1	1	0	1	0.2%
C22	Liver	330	0	7	0	3	1	0	2	0	2	5	14	18	35	49	41	57	96	6.7%
C23-C24	Gallbladder etc.	73	0	0	0	0	0	0	0	2	2	2	4	9	7	6	14	7	20	1.5%
C25	Pancreas	128	0	0	0	0	0	0	0	0	3	8	10	10	18	16	16	18	29	2.6%
C30-C31	Nose, sinuses etc.	8	0	0	0	0	0	0	0	1	0	1	1	1	1	0	1	0	2	0.2%
C32	Larynx	70	0	0	0	0	0	0	8	5	1	2	3	1	1	2	1	1	6	1.4%
C33-C34	Trachea, Bronchus, Lung	343	0	0	1	1	1	0	4	0	4	12	14	22	32	46	46	66	95	7.0%
C37-C38	Other Thoracic organs	21	0	1	1	2	0	0	2	0	5	2	1	2	0	0	0	2	2	0.4%
C40-C41	Bone	71	0	0	7	10	17	6	8	5	1	2	3	1	1	2	1	1	6	1.4%
C43	Melanoma of Skin	16	0	0	0	0	0	1	0	0	0	0	0	0	0	3	0	1	9	0.3%
C44	Other Skin	208	0	0	0	0	0	4	4	4	5	12	3	13	19	15	25	21	83	4.2%
C45	Mesothelioma	12	0	0	0	0	0	0	0	0	0	0	1	2	1	1	1	2	4	0.2%
C46	Kaposi sarcoma	19	0	0	0	0	0	0	0	0	2	2	1	2	1	4	3	2	3	0.4%
C47-C49	Connective, Soft tissue	77	0	13	2	4	5	4	6	6	8	4	5	5	2	2	2	7	3	1.6%
C50	Breast	16	0	0	0	0	0	1	0	1	1	0	2	1	0	3	1	3	3	0.3%
C60	Penis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0%
C61	Prostate	311	0	0	1	0	0	0	0	0	1	1	1	15	25	30	57	54	126	6.3%
C62	Testis	80	0	4	1	1	7	12	24	7	7	8	5	2	1	0	0	0	1	1.6%
C63	Other male genital	6	0	0	1	0	0	1	0	0	0	0	1	0	1	1	1	0	1	0.1%
C64	Kidney	178	0	13	2	0	0	0	2	7	6	9	14	24	23	15	21	11	31	3.6%
C65	Renal Pelvis	3	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	2	0.1%
C66	Ureter	5	0	0	0	0	0	0	0	0	0	0	0	2	1	1	0	0	1	0.1%
C67	Bladder	182	0	0	0	0	0	0	3	6	3	5	13	15	18	25	16	30	48	3.7%
C68	Other Urinary organs	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0.0%
C69	Eye	20	0	13	0	1	0	0	0	0	2	0	0	1	0	0	1	0	2	0.4%
C70-C72	Brain, Nervous system	170	0	15	13	9	7	12	6	12	7	14	10	13	16	7	8	10	11	3.5%
C73	Thyroid	154	0	0	0	1	1	10	6	23	12	21	14	12	11	12	14	10	7	3.1%
C74	Adrenal gland	13	0	10	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0.3%
C75	Other Endocrine	8	0	0	1	2	1	0	0	0	0	1	0	1	1	0	0	0	0	0.2%
C81	Hodgkin disease	184	0	4	5	16	29	34	21	17	11	10	6	10	3	4	1	4	9	3.7%
C82-C85-C96	Non-Hodgkin lymphoma	432	0	15	18	14	17	15	26	19	19	19	34	38	42	29	37	31	59	8.8%
C88	Immunoproliferative dis.	1	0	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0	0.0%
C90	Multiple Myeloma	50	0	0	0	0	0	0	0	1	1	5	3	5	4	5	11	3	11	1.0%
C91	Lymphoid Leukaemia	202	0	46	45	18	20	9	4	3	2	5	5	5	6	12	6	5	11	4.1%
C92-C94	Myeloid Leukaemia	148	0	7	6	10	9	9	6	9	12	10	11	8	9	11	10	6	15	3.0%
C95	Leukaemia unspec.	16	0	3	4	0	0	0	0	1	0	1	1	0	0	0	1	2	2	0.3%
Other	Other & unspecified	169	1	5	1	1	0	5	4	3	4	9	10	21	11	13	17	18	46	3.4%
All	All sites Total	4913	2	158	109	96	128	140	148	157	186	256	295	419	410	435	509	516	949	100.0%
Not C44	All sites but C44	4705	2	158	109	96	128	136	144	153	181	244	292	406	391	420	484	495	866	95.8%

Table 5.1.2 - Number of Cancer Cases Among Saudi Females by Primary Site and Age Groups, 2011

ICD (10th)	Site	All Ages	Age Unk	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Total (%)
C00	Lip	7	0	0	0	0	0	0	0	0	1	0	0	0	1	0	1	2	2	0.1%
C01-C02	Tongue	52	0	0	0	1	1	1	1	0	1	5	6	3	6	7	1	7	9	0.9%
C03-C06	Mouth	46	0	0	1	2	2	1	3	2	2	4	3	3	5	5	2	8	8	0.8%
C07-C08	Salivary glands	22	0	0	0	0	0	0	0	0	2	2	2	1	1	2	2	0	2	0.4%
C09	Tonsil	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0.0%
C10	Other Oropharynx	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0.0%
C11	Nasopharynx	45	0	0	3	4	4	2	1	1	2	3	11	8	5	2	0	1	2	0.8%
C12-C13	Hypopharynx	16	0	0	0	0	0	1	0	0	2	0	2	1	4	1	2	0	2	0.3%
C14	Pharynx unspec.	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0%
C15	Oesophagus	58	0	0	0	0	0	1	0	1	3	2	5	2	4	4	9	10	17	1.0%
C16	Stomach	133	0	0	0	0	0	1	7	4	6	8	5	10	12	16	10	22	30	2.2%
C17	Small intestine	35	0	0	0	2	0	0	3	0	2	3	3	4	1	4	3	3	7	0.6%
C18	Colon	342	0	0	0	0	1	1	7	13	14	28	44	54	42	34	33	24	47	5.7%
C19-C20	Rectum	195	0	0	0	0	0	2	4	4	10	15	28	27	18	28	16	20	23	3.3%
C21	Anus	15	0	0	0	0	0	0	0	1	0	1	0	0	3	0	3	2	5	0.3%
C22	Liver	158	0	7	0	0	0	1	1	2	1	3	11	16	16	21	29	22	28	2.7%
C23-C24	Gallbladder etc.	90	0	0	0	0	0	1	0	0	0	4	14	7	9	10	12	11	22	1.5%
C25	Pancreas	77	0	0	0	0	1	0	0	0	2	4	5	10	12	6	11	12	14	1.3%
C30-C31	Nose, sinuses etc.	3	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	1	0.1%
C32	Larynx	6	0	0	0	0	0	0	0	0	0	0	0	0	2	0	1	1	1	0.1%
C33-C34	Trachea,Bronchus,Lung	109	0	0	1	1	1	1	0	2	1	5	6	16	17	11	9	15	24	1.8%
C37-C38	Other Thoracic organs	7	0	2	0	0	0	0	0	0	0	0	0	0	0	2	1	2	0	0.1%
C40-C41	Bone	58	0	3	4	16	7	7	4	2	1	5	2	3	1	1	1	0	2	1.0%
C43	Melanoma of Skin	15	0	1	0	1	1	1	0	0	0	3	0	3	1	0	2	2	0	0.3%
C44	Other Skin	125	0	0	0	1	2	3	1	2	5	6	10	8	13	17	15	9	33	2.1%
C45	Mesothelioma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0.0%
C46	Kaposi sarcoma	6	0	0	0	0	0	0	0	0	1	1	0	0	2	0	1	0	1	0.1%
C47-C49	Connective,Soft tissue	72	0	13	1	7	5	6	5	6	1	3	5	5	4	4	3	2	2	1.2%
C50	Breast	1590	0	1	0	0	1	11	56	114	173	240	255	237	150	111	96	72	73	26.7%
C51	Vulva	7	0	0	1	0	0	0	0	0	0	1	0	0	0	0	0	2	2	0.1%
C52	Vagina	4	0	0	0	0	0	0	0	1	0	0	0	0	2	0	0	1	0	0.1%
C53	Cervix Uteri	114	0	0	0	0	0	0	0	1	0	0	0	0	2	0	0	1	0	0.1%
C54	Corpus Uteri	318	0	0	0	0	0	2	1	3	11	28	15	11	8	7	11	4	10	1.9%
C55	Uterus unspec.	41	0	0	0	0	0	0	0	1	1	17	20	38	51	46	56	34	39	5.3%
C56	Ovary	198	0	0	0	0	0	0	0	1	1	2	8	5	3	7	3	5	6	0.7%
C57	Other Female Genital	12	0	1	0	0	0	0	0	0	1	1	3	2	15	13	1	0	0	3.3%
C58	Placenta	9	0	0	0	0	0	1	2	0	1	2	3	0	0	0	0	0	0	0.2%
C64	Kidney	112	0	15	2	3	2	5	3	3	1	7	4	14	14	15	11	6	7	1.9%
C65	Renal Pelvis	2	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0.0%
C66	Ureter	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0.0%
C67	Bladder	52	0	1	0	0	0	1	0	1	1	1	2	1	2	10	10	11	11	0.9%
C68	Other Urinary organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0%
C69	Eye	19	0	14	1	0	0	0	0	0	0	0	0	0	1	1	0	2	0	0.3%
C70-C72	Brain, Nervous system	99	0	13	13	7	7	10	7	6	2	6	5	3	4	5	3	5	3	1.7%
C73	Thyroid	646	0	0	4	14	14	53	65	87	78	75	84	70	40	20	22	14	20	10.8%
C74	Adrenal gland	5	0	2	0	0	2	0	0	1	0	0	0	0	0	0	0	0	0	0.1%
C75	Other Endocrine	4	0	0	0	0	0	2	0	0	0	0	0	0	0	0	1	0	0	0.1%
C81	Hodgkin disease	157	0	4	4	11	25	37	22	7	6	10	3	4	6	6	2	7	3	2.6%
C82-C85;C96	Non-Hodgkin lymphoma	312	0	7	5	8	8	17	20	11	22	15	22	23	21	25	30	33	45	5.2%
C88	Immunoproliferative dis.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0%
C90	Multiple Myeloma	47	0	0	0	0	0	0	0	0	0	0	4	7	3	6	3	5	11	0.8%
C91	Lymphoid Leukaemia	142	0	56	21	15	6	4	5	4	3	3	4	0	4	6	4	2	5	2.4%
C92-C94	Myeloid Leukaemia	176	0	12	7	10	15	11	10	14	10	12	18	12	19	6	6	4	10	3.0%
C95	Leukaemia unspec.	13	0	2	1	1	0	1	0	0	1	1	0	1	1	0	1	1	2	0.2%
Other	Other & unspecified	178	0	3	1	2	0	1	4	7	5	12	13	15	27	12	24	18	34	3.0%
All	All sites Total	5956	0	157	61	94	115	195	244	319	393	562	650	651	553	473	472	430	587	100.0%
Not C44	All sites but C44	5831	0	157	61	93	113	192	243	317	388	556	640	643	540	456	457	421	554	97.9%

Table 5.1.3 - Age-Specific Incidence Rate (AIR), Age-Standardized Incidence Rate (ASIR) Among Saudi Males (per 100,000) by Primary Site and Age Groups, 2011

ICD (10th)	Site	All Ages	Age Unk	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Crude Rate	ASR World
C00	Lip	8	0	0	0	0	0	0	0.1	0.1	0.3	0.2	0	0.3	0	0	0.8	0	2.5	0.1%	0.1
C01-C02	Tongue	44	0	0	0	0	0	0.2	0	0.1	0.5	0.8	1.9	0.9	0.8	1.6	3.9	10.3	3.3	0.5%	0.7
C03-C06	Mouth	41	0	0	0	0	0	0	0	0.1	0.6	0.4	0.5	0.6	0.4	1.6	4.6	6.9	11.6	0.4%	0.7
C07-C08	Salivary glands	14	1	0.2	0	0	0	0	0.1	0.1	0.2	0.6	0.5	0	0	0	0.8	1.1	0.8	0.1%	0.2
C09	Tonsil	4	0	0	0	0	0	0	0	0	0	0	0	0.3	0.4	0	0	1.1	0	0.0%	0.1
C10	Other Oropharynx	3	0	0	0	0	0	0	0	0	0	0	0	0.3	0.4	0	0	0	0	0.0%	0
C11	Nasopharynx	121	0	0	0	0	0	0.3	0.1	0.7	1.3	3.7	3.3	4.8	3.2	6.6	6.2	11.5	6.6	1.2%	1.8
C12-C13	Hypopharynx	9	0	0	0	0	0	0	0	0	0	0.2	0	0	0	0.5	0.8	2.3	3.3	0.1%	0.2
C14	Pharynx unsp.pec.	3	0	0	0	0	0	0	0	0	0	0	0	0.3	0	0.5	0	0	0	0.0%	0
C15	Oesophagus	76	0	0	0	0	0	0	0.2	0	0.8	0.4	0.7	1.2	2	4.4	3.1	17.2	23.1	0.8%	1.3
C16	Stomach	162	0	0	0	0	0	0.2	0.2	0.7	1	1	2.1	6.8	6	8.8	13.2	28.7	30.5	1.7%	2.8
C17	Small intestine	35	0	0	0	0	0	0.1	0.1	0.1	0.3	0.2	1.2	1.8	2	0.5	3.1	2.3	5	0.4%	0.6
C18	Colon	378	0	0	0	0	0	0.6	0.8	3.2	4.2	7.6	7.6	17.3	17.1	21.4	45.7	42.5	46.2	3.9%	6.6
C19-C20	Rectum	279	0	0	0	0	0	0.7	0.7	1.2	1.9	4.4	6.4	9.2	12.3	15.4	31	29.9	31.4	2.9%	4.7
C21	Anus	11	0	0	0	0	0	0	0	0.1	0.3	0.2	0	0.9	0.4	0.5	0.8	0	0.8	0.1%	0.2
C22	Liver	330	0	0.6	0	0.3	0.1	0	0.2	0	0.3	0.4	0.9	2.7	2.8	3.3	10.8	8	16.5	0.7%	1.3
C23-C24	Gallbladder etc.	73	0	0	0	0	0	0	0	0.3	0.3	0.4	0.2	0.3	0.4	0	0.8	0	23.9	1.3%	2.3
C25	Pancreas	128	0	0	0	0	0	0	0	0.1	0.5	1.5	2.4	3	7.2	8.8	12.4	20.7	23.9	1.3%	2.3
C30-C31	Nose, sinuses etc.	8	0	0	0	0	0	0	0	0	0	0.2	0.2	0.3	0.4	0	0.8	0	1.7	0.1%	0.1
C32	Larynx	70	0	0	0	0	0	0	0	0	0.3	0.8	0.7	3.3	3.2	5.5	8.5	12.6	8.3	0.7%	1.3
C33-C34	Trachea,Bronchus,Lung	343	0	0	0.1	0.1	0.1	0	0.5	0	0.6	2.3	3.3	6.5	12.7	25.3	35.6	75.8	78.4	3.5%	6.4
C37-C38	Other Thoracic organs	21	0	0.1	0.1	0.2	0	0	0.2	0	0.8	0.4	0.2	0.6	0	0	0	2.3	1.7	0.2%	0.3
C40-C41	Bone	71	0	0	0.6	0.9	1.7	0.6	0.9	0.7	0.2	0.4	0.7	0.3	0.4	1.1	0.8	1.1	5	0.7%	0.8
C43	Melanoma of Skin	16	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0%	0
C44	Other Skin	208	0	0	0	0	0	0.4	0.5	0.5	0.8	2.3	0.7	3.9	7.6	8.2	19.4	24.1	68.5	2.1%	3.6
C45	Mesothelioma	12	0	0	0	0	0	0	0	0	0	0	0.2	0.6	0.4	0.5	0.8	2.3	3.3	0.1%	0.2
C46	Kaposi sarcoma	19	0	0	0	0	0	0	0	0	0.3	0.4	0.2	0.6	0.4	2.2	2.3	1.1	2.5	0.2%	0.3
C47-C49	Connective,Soft tissue	77	0	1	0.2	0.4	0.5	0.4	0.7	0.8	1.3	0.8	1.2	1.5	0.8	0.5	1.5	8	2.5	0.8%	0.9
C50	Breast	16	0	0	0	0.1	0	0	0	0.1	0.2	0	0.5	0.3	0	1.6	0.8	3.4	2.5	0.2%	0.3
C60	Penis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0%	0
C61	Prostate	311	0	0	0.1	0	0	0	0	0	0.2	0.2	0.2	0.5	10	16.5	44.1	62	104	3.2%	6
C62	Testis	80	0	0.3	0.1	0.1	0.7	1.3	2.8	1	1.1	1.5	1.2	0.6	0.4	0	0	0	0.8	0.8%	0.8
C63	Other male genital	6	0	0	0	0	0	0	0	0	0	0	0	0	0.4	0.5	0	0	0.8	0.1%	0.1
C64	Kidney	178	0	1	0.2	0	0	0	0.2	1	1	1.7	3.3	7.1	9.2	8.2	16.3	12.6	25.6	1.8%	2.9
C65	Renal Pelvis	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1.7	0.0%	0
C66	Ureter	5	0	0	0	0	0	0	0	0	0	0	0	0.6	0.4	0.5	0	0	0.8	0.1%	0.1
C67	Bladder	182	0	0	0	0	0	0	0.4	0.8	0.5	1	3.1	4.5	7.2	13.7	12.4	34.4	39.6	1.9%	3.3
C68	Other Urinary organs	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1.1	0	0.0%	0
C69	Eye	20	0	1	0	0	0	0	0	0	0.3	0	0	0.3	0	0	0	0	1.7	0.2%	0.2
C70-C72	Brain, Nervous system	170	0	1.2	1.1	0.8	0.7	1.3	0.7	1.6	1.1	2.7	2.4	3.9	6.4	3.8	6.2	11.5	9.1	1.7%	2.2
C73	Thyroid	154	0	0	0	0	0	1.1	0.7	3.1	1.9	4	3.3	3.6	4.4	6.6	10.8	11.5	5.8	1.6%	2.2
C74	Adrenal gland	13	0	0.8	0	0	0	0	0	0	0.2	0	0.2	0	0	0	0	0	0	0.1%	0.1
C75	Other Endocrine	8	0	0	0	0	0	0	0	0	0	0.2	0	0.3	0.4	0	0	0	0	0.1%	0.1
C81	Hodgkin disease	184	0	0.3	0.4	1.5	2.8	3.6	2.5	2.3	1.8	1.9	1.4	3	1.2	2.2	0.8	4.6	7.4	1.9%	1.9
C82-C85;C96	Non-Hodgkin lymphoma	432	0	1.2	1.6	1.3	1.7	1.6	3.1	2.6	3	3.7	8	11.3	16.7	15.9	28.7	35.6	48.7	4.4%	6.4
C88	Immunoproliferative dis.	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0%	0
C90	Multiple Myeloma	50	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.0%	0
C91	Lymphoid Leukaemia	202	0	3.6	3.9	1.7	1.9	0.9	0.5	0.4	0.3	1	1.2	1.5	2.4	6.6	4.6	5.7	9.1	2.1%	2.3
C92-C94	Myeloid Leukaemia	148	0	0.6	0.5	0.9	0.9	0.9	0.7	1.2	1.9	1.9	2.6	2.4	3.6	6	7.7	6.9	12.4	1.5%	2
C95	Leukaemia unsp.pec.	16	0	0.2	0.3	0	0	0	0	0	0	0	0	0	0	0	0	0	1.7	0.2%	0.2
Other	Other & unspecified	169	1	0.4	0.1	0.1	0	0.5	0.5	0.4	0.6	1.7	2.4	6.2	4.4	7.1	13.2	20.7	38	1.7%	2.8
All	All sites Total	4913	2	13	9	9	12	15	18	21	30	49	70	125	163	239	394	592	783	50.5%	78.8
Not C44	All sites but C44	4705	2	13	9	9	12	14	17	21	29	47	69	121	156	231	375	588	715	48.3%	75.2

Table 5.1.4 - Age-Specific Incidence Rate (AIR), Age-Standardized Incidence Rate (ASR) Among Saudi Females (per 100,000) by Primary Site and Age Groups, 2011

ICD (10th)	Site	All Ages	Age Unk	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Crude Rate	ASR World
C00	Lip	7	0	0	0	0	0	0	0	0	0.2	0	0	0	0.4	0	0.8	2.2	1.7	0.1	0.1
C01-C02	Tongue	52	0	0	0	0	0	0.1	0.1	0	0.2	1	1.5	2.5	2.5	4	0.8	7.7	7.4	0.5	0.9
C03-C06	Mouth	46	0	0	0	0.1	0.2	0.1	0.1	0.3	0.2	0.8	0.7	0.9	2.1	2.8	1.5	8.7	6.6	0.5	0.8
C07-C08	Salivary glands	22	0	0	0	0	0.2	0.1	0.3	0.3	0.3	0.4	0.5	0.3	0.4	1.1	1.5	0	1.7	0.2	0.3
C09	Tonsil	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C10	Other Oropharynx	1	0	0	0	0	0	0	0	0	0	0.2	0	0	0	0	0	0	0	0	0
C11	Nasopharynx	45	0	0	0	0.3	0.4	0.2	0.1	0.1	0.3	0.6	2.7	2.5	2.1	1.1	0	1.1	1.7	0.5	0.6
C12-C13	Hypopharynx	16	0	0	0	0	0	0.1	0	0	0.3	0.2	0.5	0.3	1.7	0.6	1.5	0	1.7	0.2	0.3
C14	Pharynx unsp.	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1.7	0	0
C15	Oesophagus	58	0	0	0	0	0	0.1	0	0.1	0.5	0.4	1.2	0.6	1.7	2.3	6.9	10.9	14.1	0.6	1
C16	Stomach	133	0	0	0	0	0.1	0.2	0.8	0.5	1	1.6	1.2	3.1	5	9.1	7.7	24	24.8	1.4	2.3
C17	Small intestine	35	0	0	0	0	0.2	0	0.3	0	0.3	0.6	0.7	1.2	0.4	2.3	2.3	3.3	5.8	0.4	0.6
C18	Colon	342	0	0	0	0	0.1	0.1	0.8	1.7	2.2	5.4	10.7	16.8	17.5	19.2	25.3	26.2	38.9	3.5	5.7
C19-C20	Rectum	195	0	0	0	0	0.2	0.2	0.5	0.5	1.6	2.9	6.8	8.4	7.5	15.8	12.2	21.9	19	2	3.3
C21	Anus	15	0	0	0	0	0	0	0.1	0	0	0.2	0	0	1.2	0	2.3	2.2	4.1	0.2	0.3
C22	Liver	158	0	0.6	0	0	0	0.1	0.1	0.3	0.2	0.6	2.7	5	6.7	11.9	22.2	24	23.2	1.6	2.9
C23-C24	Gallbladder etc.	90	0	0	0	0	0	0.1	0	0	0	0.8	3.4	2.2	3.7	5.7	9.2	12	18.2	0.9	1.6
C25	Pancreas	77	0	0	0	0	0.1	0	0	0	0.3	0.8	1.2	3.1	5	3.4	8.4	13.1	11.6	0.8	1.4
C30-C31	Nose, sinuses etc.	3	0	0	0	0	0	0	0	0	0	0	0.2	0.3	0	0	0	0	0.8	0	0
C32	Larynx	6	0	0	0	0	0	0	0	0	0	0	0	0	0.8	0.6	0.8	1.1	0.8	0.1	0.1
C33-C34	Trachea, Bronchus, Lung	109	0	0	0	0.1	0.1	0.1	0	0.3	0.2	1	1.5	5	7.1	6.2	6.9	16.4	19.8	1.1	1.9
C37-C38	Other Thoracic organs	7	0	0.2	0	0	0	0	0	0	0	0	0	0	0	1.1	0.8	2.2	0	0.1	0.1
C40-C41	Bone	58	0	0.2	0.4	1.5	0.7	0.7	0.5	0.3	0.2	1	0.5	0.6	0.4	0.6	0.8	0	1.7	0.6	0.6
C43	Melanoma of Skin	15	0	0.1	0	0	0.1	0.1	0	0.1	0	0.6	0	0.9	0.4	0	1.5	2.2	0	0.2	0.2
C44	Other Skin	125	0	0	0	0.1	0.2	0.3	0.1	0.3	0.8	1.2	2.4	2.5	5.4	9.6	11.5	9.8	27.3	1.3	2.2
C45	Mesothelioma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1.1	0	0	0
C46	Kaposi sarcoma	6	0	0	0	0	0	0	0	0	0.2	0.2	0	0	0.8	0	0.8	0	0.8	0.1	0.1
C47-C49	Connective, Soft tissue	72	0	1.1	0.1	0.7	0.5	0.6	0.6	0.8	0.2	0.6	1.2	1.6	1.7	2.3	2.3	2.2	1.7	0.7	0.9
C50	Breast	1590	0	0.1	0	0	0.1	1.1	6.5	15.2	27.5	46.5	62.1	73.9	62.4	62.8	73.5	78.7	60.4	16.5	23.4
C51	Vulva	7	0	0	0.1	0	0	0	0	0	0	0.2	0	0.3	0	0	0	2.2	1.7	0.1	0.1
C52	Vagina	4	0	0	0	0	0	0	0	0.1	0	0	0	0	0.8	0	0	1.1	0	0	0.1
C53	Cervix Uteri	114	0	0	0	0	0	0	0.1	0.8	2.1	5.4	3.7	3.4	3.3	4	8.4	4.4	8.3	1.2	1.7
C54	Corpus Uteri	318	0	0	0	0	0.2	0.2	0.1	0.4	1.8	3.3	4.9	11.9	21.2	26	42.9	37.2	32.3	3.3	5.8
C55	Uterus unsp.	41	0	0	0	0	0	0	0	0.1	0.2	0.4	1.9	1.6	1.2	4	2.3	5.5	5	0.4	0.7
C56	Ovary	198	0	0	0.4	0.6	0.7	1.2	1.3	1.3	3.3	4.4	6.6	6.6	6.2	7.4	15.3	29.5	18.2	2.1	3.1
C57	Other Female Genital	12	0	0.1	0	0	0	0.4	0.7	0.3	0.8	0.6	0.8	0	0	0	0	0	0	0.1	0.2
C58	Placenta	9	0	0	0	0	0	0.1	0.2	0	0.2	0.4	0.7	0	0	0	0	0	0	0.1	0.1
C64	Kidney	112	0	1.2	0.2	0.3	0.2	0.5	0.3	0.4	0.2	1.4	1	4.4	5.8	8.5	8.4	6.6	5.8	1.2	1.7
C65	Renal Pelvis	2	0	0	0	0	0	0	0	0	0	0	0.2	0	0	0	0	1.1	0	0	0
C66	Ureter	2	0	0	0	0	0	0	0	0	0	0	0	0	0.4	0	0	0	0	0	0
C67	Bladder	52	0	0.1	0	0	0	0.1	0	0.1	0.2	0.2	0.5	0.3	0.8	5.7	7.7	12	9.1	0.5	1
C68	Other Urinary organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C69	Eye	19	0	1.2	0.1	0	0	0	0	0	0	0	0	0	0.4	0.6	0	2.2	0	0.2	0.2
C70-C72	Brain, Nervous system	99	0	1.1	1.2	0.7	0.7	1	0.8	0.8	0.3	1.2	1.2	0.9	1.7	2.8	2.3	5.5	2.5	1	1.2
C73	Thyroid	646	0	0	0.4	1.3	5.5	5.5	7.5	11.6	12.4	14.5	20.5	21.8	16.6	11.3	16.8	15.3	16.5	6.7	8.1
C74	Adrenal gland	5	0	0.2	0	0	0.2	0	0	0.1	0	0	0	0	0	0	0	0	0	0.1	0
C75	Other Endocrine	4	0	0	0	0	0	0.2	0	0	0	0	0	0.3	0	0	0.8	0	0	0	0.1
C81	Hodgkin disease	157	0	0.3	0.4	1	2.4	3.8	2.5	0.9	1	1.9	0.7	1.2	2.5	3.4	1.5	7.7	2.5	1.6	1.7
C82-C85;C96	Non-Hodgkin lymphoma	312	0	0.6	0.4	0.7	0.8	1.8	2.3	1.5	3.5	2.9	5.4	7.2	8.7	14.2	23	36.1	37.2	3.2	4.8
C88	Immunoproliferative dis.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C90	Multiple Myeloma	47	0	0	0	0	0	0	0	0	0	0.8	1.9	2.2	1.2	3.4	2.3	5.5	9.1	0.5	0.8
C91	Lymphoid Leukaemia	142	0	4.6	1.9	1.4	0.6	0.4	0.6	0.5	0.5	0.6	1	0	1.7	3.4	3.1	2.2	4.1	1.5	1.6
C92-C94	Myeloid Leukaemia	176	0	1	0.6	0.9	1.4	1.1	1.2	1.9	1.6	2.3	4.4	3.7	7.9	3.4	4.6	4.4	8.3	1.8	2.2
C95	Leukaemia unsp.	13	0	0.2	0.1	0.1	0	0.1	0	0	0.2	0.2	0	0.3	0.4	0	0.8	1.1	1.7	0.1	0.2
Other	Other & unspecified	178	0	0.2	0.1	0.2	0	0.1	0.5	0.9	0.8	2.3	3.2	4.7	11.2	6.8	18.4	19.7	28.1	1.8	3
All	All sites Total	5956	0	13	5	9	11	20	28	43	63	109	158	203	230	268	361	470	485	61.7	90.1
Not C44	All sites but C44	5831	0	13	5	9	11	20	28	42	62	108	156	201	225	258	350	460	458	60.4	88

Table 5.4.1 - Number of Cancer Cases Among Non-Saudi Males by Primary Site and Age Groups, 2011

ICD (10th)	Site	All Ages	Age Unk	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Total (%)	
C00	Lip	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.20%	
C01-C02	Tongue	21	0	0	0	0	0	0	1	1	3	5	1	1	3	3	0	0	0	1.20%	
C03-C06	Mouth	17	0	0	0	0	0	0	0	1	3	5	1	1	3	0	1	2	1	1.00%	
C07-C08	Salivary glands	9	0	0	0	0	0	0	1	1	2	2	0	1	0	2	0	0	0	0.50%	
C09	Tonsil	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%	
C10	Other Oropharynx	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.10%	
C11	Nasopharynx	49	0	0	4	1	3	2	2	1	5	7	7	10	4	2	1	1	1	2.90%	
C12-C13	Hypopharynx	2	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0.10%	
C14	Pharynx unsp.	25	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%	
C15	Oesophagus	76	0	0	0	0	0	1	2	2	4	5	2	4	6	4	3	1	1	1.50%	
C16	Stomach	13	0	0	0	0	0	0	0	5	4	5	9	15	15	6	5	6	3	4.50%	
C17	Small intestine	166	0	0	0	0	0	1	5	7	2	18	22	29	35	12	17	7	7	9.80%	
C18	Colon	90	0	0	0	0	0	0	6	5	4	9	10	19	18	6	5	3	5	5.30%	
C19-C20	Rectum	7	0	0	0	0	0	0	0	1	1	2	1	1	1	0	1	0	0	0.40%	
C21	Anus	48	0	1	0	0	0	1	0	1	0	2	9	10	4	8	4	5	3	2.80%	
C22	Liver	21	0	0	0	0	0	0	1	1	2	2	0	4	4	2	3	1	1	1.20%	
C23-C24	Gallbladder etc.	23	0	0	0	0	0	0	0	0	0	0	0	6	6	4	5	3	0	1.40%	
C25	Pancreas	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0.10%	
C30-C31	Nose, sinuses etc.	25	0	0	0	0	1	0	0	0	0	2	3	5	2	2	2	5	3	1.50%	
C32	Larynx	106	0	0	0	1	1	1	0	2	4	12	8	18	21	13	14	9	2	6.30%	
C33-C34	Trachea, Bronchus, Lung	9	0	0	0	0	0	0	0	0	0	3	2	1	1	2	0	0	0	0.50%	
C37-C38	Other Thoracic organs	16	0	0	0	0	0	0	1	0	1	0	1	4	3	2	0	0	0	0.90%	
C40-C41	Bone	122	0	1	2	1	1	1	2	0	1	0	1	4	2	2	0	0	1	0.60%	
C43	Melanoma of Skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.20%	
C44	Other Skin	3	0	0	0	0	0	0	3	3	9	14	9	24	32	17	3	5	2	7.20%	
C45	Mesothelioma	0	0	0	0	0	0	0	0	0	0	0	1	0	2	0	0	0	0	0.20%	
C46	Kaposi sarcoma	26	0	4	0	0	1	2	0	3	0	0	0	2	4	1	0	2	0	1.50%	
C47-C49	Connective, Soft tissue	12	0	0	0	0	0	0	1	0	0	1	1	1	3	3	1	0	1	0.70%	
C50	Breast	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.10%	
C60	Penis	122	0	0	0	0	0	0	0	0	0	2	6	15	25	23	23	16	12	7.20%	
C61	Prostate	17	0	2	0	0	1	1	6	1	1	3	0	1	0	1	0	0	0	1.00%	
C62	Testis	2	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0.10%	
C63	Other male genital	57	0	3	0	0	0	2	1	0	5	8	7	12	6	6	3	4	0	3.40%	
C64	Kidney	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0.10%	
C65	Renal Pelvis	2	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0.10%	
C66	Ureter	80	0	0	0	0	0	1	0	0	1	8	9	10	19	12	6	9	5	4.70%	
C67	Bladder	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.10%	
C68	Other Urinary organs	5	0	1	1	0	0	0	1	0	1	0	0	0	1	0	0	0	1	0.30%	
C69	Eye	52	0	3	7	2	3	0	2	6	11	3	4	7	2	2	3	2	1	3.10%	
C70-C72	Brain, Nervous system	51	0	0	0	0	0	2	1	6	5	4	7	9	5	1	4	1	0	3.00%	
C73	Thyroid	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%	
C74	Adrenal gland	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%	
C75	Other Endocrine	53	0	0	1	0	0	0	0	0	0	0	0	1	1	1	2	0	1	3.10%	
C81	Hodgkin disease	128	0	2	2	1	4	7	10	11	9	8	12	26	16	10	6	2	2	7.60%	
C82-C85;C96	Non-Hodgkin lymphoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%	
C88	Immunoproliferative dis.	24	0	0	0	0	0	0	0	1	1	2	1	5	6	2	2	1	2	1.40%	
C90	Multiple Myeloma	43	0	6	8	2	3	3	0	4	1	1	3	2	2	2	3	2	1	2.50%	
C91	Lymphoid Leukaemia	44	0	3	2	2	1	4	4	2	5	6	6	6	2	2	1	0	2	2.60%	
C92-C94	Myeloid Leukaemia	6	0	0	0	0	0	0	0	2	0	1	0	0	2	1	0	0	0	0.40%	
C95	Leukaemia unsp.	94	0	1	1	0	0	1	1	8	4	8	8	19	17	10	2	9	5	5.60%	
Other	Other & unspecified	1690	0	28	23	14	21	36	63	82	102	156	172	272	274	163	120	96	68	100.00%	
All	All sites Total	1568	0	27	23	14	21	36	60	79	93	142	163	248	242	146	117	91	66	92.80%	
Not.C44	All sites but C44		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	

Table 5.4.2 - Number of Cancer Cases Among Non-Saudi Females by Primary Site and Age Groups, 2011

ICD (10th)	Site	All Ages	Age Unk	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Total (%)
C00	Lip	2	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0.10%
C01-C02	Tongue	11	0	0	0	0	0	0	0	1	3	0	0	3	1	2	0	0	1	0.70%
C03-C06	Mouth	9	0	0	0	0	0	0	0	0	0	3	0	0	1	3	1	0	1	0.50%
C07-C08	Salivary glands	6	0	0	0	0	0	0	1	0	0	1	2	0	0	3	1	0	0	0.40%
C09	Tonsil	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0.10%
C10	Other Oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C11	Nasopharynx	9	0	0	0	1	1	0	1	1	2	2	0	0	2	0	0	0	0	0.50%
C12-C13	Hypopharynx	3	0	0	0	1	1	0	1	0	0	0	1	1	0	0	0	0	0	0.20%
C14	Pharynx unsp. spec.	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0.10%
C15	Oesophagus	7	0	0	0	0	0	0	0	0	0	0	0	2	1	1	1	1	1	0.40%
C16	Stomach	31	0	0	0	1	0	1	0	0	4	0	5	6	1	6	5	2	1	1.90%
C17	Small intestine	4	0	0	0	0	1	0	0	0	0	0	3	0	1	0	0	0	1	0.20%
C18	Colon	80	0	0	0	0	0	0	3	2	9	9	13	4	9	10	6	4	11	4.80%
C19-C20	Rectum	41	0	1	0	0	0	0	0	3	5	2	7	7	4	4	3	2	3	2.50%
C21	Anus	6	0	0	0	0	0	0	0	0	0	3	0	0	1	2	0	0	0	0.40%
C22	Liver	17	0	1	0	1	0	0	0	1	1	1	1	1	1	2	3	1	4	1.00%
C23-C24	Gallbladder etc.	15	0	0	0	0	0	1	0	0	0	3	2	4	3	1	0	0	1	0.90%
C25	Pancreas	14	0	0	0	0	0	0	0	0	0	1	1	4	5	2	1	1	0	0.80%
C30-C31	Nose, sinuses etc.	6	0	1	0	0	0	0	0	2	0	1	0	1	1	0	0	0	0	0.40%
C32	Larynx	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0.10%
C33-C34	Trachea, Bronchus, Lung	29	0	0	0	1	0	0	1	0	0	1	2	2	6	8	3	1	4	1.70%
C37-C38	Other Thoracic organs	2	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0.10%
C40-C41	Bone	13	0	0	1	4	0	3	1	1	0	1	2	0	0	1	0	0	0	0.80%
C43	Melanoma of Skin	5	0	0	0	0	0	0	0	0	2	1	0	0	2	0	0	0	0	0.30%
C44	Other Skin	43	0	0	0	0	0	0	3	3	4	3	4	5	7	4	2	4	4	2.60%
C45	Mesothelioma	3	0	0	0	0	0	0	0	0	1	0	1	1	0	0	0	0	0	0.20%
C46	Kaposi sarcoma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.10%
C47-C49	Connective, Soft tissue	22	0	1	1	2	1	1	2	2	0	5	2	2	1	0	1	1	1	1.30%
C50	Breast	659	0	0	4	4	1	4	24	58	76	117	112	105	67	42	25	18	10	39.60%
C51	Vulva	2	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0.10%
C52	Vagina	2	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0.10%
C53	Cervix Uteri	71	0	0	0	0	0	0	2	3	9	13	10	13	7	5	3	0	6	4.30%
C54	Corpus Uteri	69	0	0	0	0	0	1	0	0	4	9	8	10	17	10	8	1	1	4.10%
C55	Uterus unsp. spec.	14	0	0	0	0	0	0	0	2	1	0	1	4	1	2	3	0	0	0.80%
C56	Ovary	66	0	0	0	1	3	0	1	4	6	5	9	8	11	4	10	1	4	4.00%
C57	Other Female Genital	4	0	0	0	0	0	0	1	0	0	0	2	0	1	0	0	0	0	0.20%
C58	Placenta	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.10%
C64	Kidney	29	0	5	1	0	1	0	1	0	3	4	5	5	0	1	1	1	1	1.70%
C65	Renal Pelvis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C66	Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C67	Bladder	12	0	0	0	0	0	0	0	0	2	0	3	2	1	1	0	1	2	0.70%
C68	Other Urinary organs	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.10%
C69	Eye	6	0	1	0	0	0	0	2	1	1	0	0	0	0	0	0	1	0	0.40%
C70-C72	Brain, Nervous system	25	0	1	1	2	2	0	12	0	3	2	2	3	0	1	3	1	0	1.50%
C73	Thyroid	109	0	0	1	3	8	8	12	22	15	16	10	5	7	4	1	4	1	6.60%
C74	Adrenal gland	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C75	Other Endocrine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C81	Hodgkin disease	27	0	0	0	4	5	7	3	3	0	0	1	0	1	0	1	1	1	1.60%
C82-C85;C96	Non-Hodgkin lymphoma	45	0	0	1	2	2	2	0	5	3	3	5	7	7	4	3	1	2	2.70%
C88	Immunoproliferative dis.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C90	Multiple Myeloma	13	0	0	0	1	0	0	0	0	0	0	0	2	3	3	1	0	3	0.80%
C91	Lymphoid Leukaemia	24	0	10	6	3	1	3	0	0	0	0	0	0	1	0	0	0	0	1.40%
C92-C94	Myeloid Leukaemia	28	0	3	1	1	1	3	4	3	3	2	1	2	1	0	0	3	0	1.70%
C95	Leukaemia unsp. spec.	8	0	0	1	1	0	1	0	1	0	0	0	0	0	0	0	0	1	0.50%
Other	Other & unspecified	66	0	0	0	2	0	0	3	3	7	4	11	6	7	11	4	5	3	4.00%
All	All sites Total	1663	0	24	12	22	27	39	67	121	165	210	229	218	179	137	90	56	67	100.00%
Not C44	All sites but C44	1620	0	24	12	22	27	39	64	118	161	207	225	213	172	133	88	52	63	97.40%

Table 5.4.3 - Age-Specific Rate (AIR), Age-Standardized Incidence Rate (ASR) Among Non-Saudi Males (per 100,000) by Primary Site and Age Groups, 2011

ICD (10th)	Site	All Ages	Age Unk	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Crude Rate	ASR World
C00	Lip	4	0	0	0	0	0	0	0	0	0	0	0.6	0	0	0	0	0	0	0.1	0
C01-C02	Tongue	21	0	0	0	0	0	0	0.2	0.1	0.3	0.6	0.2	0.3	1.4	3.3	0	0	19.5	0.3	0.7
C03-C06	Mouth	17	0	0	0	0	0	0	0	0	0.3	0.6	0.2	0.3	1.4	0	3.1	13.9	6.5	0.3	0.6
C07-C08	Salivary glands	9	0	0	0	0	0	0	0.2	0.1	0.2	0.2	0	0.3	0	2.2	0	0	0	0.1	0.1
C09	Tonsil	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C10	Other Oropharynx	1	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	0	0
C11	Nasopharynx	49	0	0	0	1.4	0.5	1.3	0.4	0.1	0.4	0.8	1.1	2.6	1.9	2.2	3.1	7	6.5	0.8	1.1
C12-C13	Hypopharynx	2	0	0	0	0	0	0	0	0	0	0	0.2	0	0	1.1	0	0	0	0	0.1
C14	Pharynx unsp.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C15	Oesophagus	25	0	0	0	0	0	0.4	0.4	0.5	0.4	0.2	0.3	1	2.8	4.4	9.2	7	6.5	0.4	0.9
C16	Stomach	76	0	0	0	0	0	0.4	0.4	0.5	0.4	0.6	1.4	3.9	6.9	6.6	15.3	41.8	19.5	1.2	2.7
C17	Small intestine	13	0	0	0	0	0	0	0	0.1	0.2	0.2	0.6	1	0	0	0	0	0	0.2	0.1
C18	Colon	166	0	0	0	0	0	0.4	1	0.7	0.5	2	3.5	7.5	16.2	13.3	52.1	48.7	45.5	2.6	5.5
C19-C20	Rectum	90	0	0	0	0	0	0	1.2	0.5	0.4	1	1.6	4.9	8.3	6.6	15.3	20.9	32.5	1.4	2.7
C21	Anus	7	0	0	0	0	0	0	0	0.1	0.1	0.1	0.2	0.3	0.5	0	3.1	0	0	0.1	0.2
C22	Liver	48	0	0.3	0	0	0	0.4	0	0.1	0	0.2	1.4	2.6	1.9	8.8	12.3	34.8	19.5	0.8	2.2
C23-C24	Gallbladder etc.	21	0	0	0	0	0	0	0.2	0.1	0.2	0.2	0	1	1.9	2.2	9.2	7	6.5	0.3	0.8
C25	Pancreas	23	0	0	0	0	0	0	0	0	0	0	0.8	0	2.8	4.4	15.3	20.9	0	0.4	1.2
C30-C31	Nose, sinuses etc.	2	0	0	0	0	0	0	0	0	0	0	0	0.5	0	0	0	0	6.5	0	0.1
C32	Larynx	25	0	0	0	0.5	0	0	0	0	0	0.2	0.5	1.3	0.9	2.2	6.1	34.8	19.5	0.4	1.5
C33-C34	Trachea, Bronchus, Lung	106	0	0	0.4	0.5	0.4	0.4	0	0.2	0.4	1.4	1.3	4.6	9.7	14.4	42.9	62.6	13	1.7	4.3
C37-C38	Other Thoracic organs	9	0	0	0	0	0	0	0	0	0	0.3	0.3	0.3	0.5	2.2	0	0	0	0.1	0.2
C40-C41	Bone	16	0	0.3	0	0.7	0.5	0.4	0.4	0	0.1	0.1	0.2	1	1.4	0	0	0	0	0.3	0.3
C43	Melanoma of Skin	10	0	0	0	0	0	0	0.2	0	0.1	0.1	0.2	0.3	0.9	2.2	0	0	6.5	0.2	0.3
C44	Other Skin	122	0	0.3	0	0	0	0	0.6	0.3	0.8	1.6	1.4	6.2	14.8	18.8	9.2	34.8	13	1.9	3.2
C45	Mesothelioma	3	0	0	0	0	0	0	0	0	0	0	0.2	0	0.9	0	0	0	0	0	0
C46	Kaposi sarcoma	3	0	0	0	0	0	0	0	0.1	0	0	0	0.5	0	0	0	0	0	0	0
C47-C49	Connective, Soft tissue	26	0	1.2	0	0	0.5	0.9	0.4	0.3	0	0.2	0.3	0.8	1.9	1.1	0	13.9	0	0.4	0.8
C50	Breast	12	0	0	0	0	0	0	0.2	0	0	0.1	0.2	0.3	1.4	3.3	3.1	0	6.5	0.2	0.5
C60	Penis	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6.5	0	0.1
C61	Prostate	122	0	0	0	0	0	0	0	0	0	0.2	1	3.9	11.6	25.4	70.5	111.3	78	1.9	7.6
C62	Testis	17	0	0.6	0	0.5	0.4	0.4	1.2	0.1	0.1	0.3	0	0.3	0	1.1	0	0	0	0.3	0.3
C63	Other male genital	2	0	0	0	0	0	0	0	0	0.2	0	0	0	0	0	0	0	0	0	0
C64	Kidney	57	0	0.9	0	0	0	0.9	0.2	0	0.4	0.9	1.1	3.1	2.8	6.6	9.2	27.8	0	0.9	1.7
C65	Renal Pelvis	1	0	0	0	0	0	0	0	0	0	0	0	0.3	0	0	0	0	0	0	0
C66	Ureter	2	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	0	0
C67	Bladder	80	0	0	0	0	0	0.4	0	0	0.1	0.9	1.4	2.6	8.8	13.3	18.4	62.6	32.5	1.3	3.6
C68	Other Urinary organs	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6.5	0	0.1
C69	Eye	5	0	0.3	0.3	0	0	0	0.2	0	0.1	0	0	0	0.5	0	0	0	0	0.1	0.1
C70-C72	Brain, Nervous system	52	0	0.9	2.2	0.7	1.4	0	0.4	0.6	0.4	0.3	0.6	1.8	0.9	2.2	9.2	13.9	6.5	0.8	1.6
C73	Thyroid	51	0	0	0	0	0	0.9	0.2	0.6	1	0.5	1.1	2.3	2.3	1.1	12.3	7	0	0.8	1
C74	Adrenal gland	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C75	Other Endocrine	1	0	0	0.3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C81	Hodgkin disease	53	0	0	0.3	0	2.4	3.6	1.7	0.6	0.7	0.6	0.8	0.3	0.5	1.1	6.1	0	6.5	0.8	1.2
C82-C85;C96	Non-Hodgkin lymphoma	128	0	0.6	0.6	0.4	1.9	3.1	1.9	1.1	0.8	0.9	1.9	6.7	7.4	11.1	18.4	13.9	13	2	3.2
C88	Immunoproliferative dis.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C90	Multiple Myeloma	24	0	0	0	0	0	0	0.2	0.1	0.1	0.2	0.2	1.3	2.8	2.2	6.1	7	13	0.4	0.9
C91	Lymphoid Leukaemia	43	0	1.8	2.5	0.7	1.4	1.3	0	0.4	0.1	0.1	0.5	0.5	0.9	2.2	9.2	13.9	6.5	0.7	1.7
C92-C94	Myeloid Leukaemia	44	0	0.9	0.6	0.7	0.4	0.4	0.8	0.2	0.4	0.7	1	1.5	0.9	2.2	3.1	0	13	0.7	1
C95	Leukaemia unsp.	6	0	0	0	0	0	0	0	0.2	0	0.1	0	0	0.9	1.1	0	0	0	0.1	0.1
Other	Other & unspecified	94	0	0.3	0.3	0	0	0.4	0.2	0.8	0.4	0.9	1.3	4.9	7.9	11.1	6.1	62.6	32.5	1.5	3.4
All	All sites Total	1690	0	9	7	5	10	16	12	8	9	18	27	70	127	180	368	668	442	26.9	58.1
Not.C44	All sites but C44	1568	0	8	7	5	10	16	12	8	8	16	26	64	112	162	359	633	429	24.9	54.9

Table 5.4.4 - Age-Specific Incidence Rate (AIR), Age-Standardized Incidence Rate (ASR) Among Non-Saudi Females (per 100,000) by Primary Site and Age Groups, 2011

ICD (10th)	Site	All Ages	Age Unk	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Crude Rate	ASR World
C00	Lip	2	0	0	0	0	0	0	0	0	0	0	0	0	0	8.9	0	0	0	0.1	0.4
C01-C02	Tongue	11	0	0	0	0	0	0	0	0.3	0.7	0	0	5	2.4	8.9	0	0	9.3	0.4	0.9
C03-C06	Mouth	9	0	0	0	0	0	0	0	0	0	1.2	0	0	2.4	13.3	7.2	0	9.3	0.3	1.1
C07-C08	Salivary glands	6	0	0.4	0	0	0	0	0.4	0	0	0	2	0	0	0	7.2	0	0	0.2	0.4
C09	Tonsil	1	0	0	0	0	0	0	0	0	0	0	0	0	0	4.4	0	0	0	0	0.2
C10	Other Oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C11	Nasopharynx	9	0	0	0	0.6	0	0	0.4	0.3	0.5	0.8	1	0	4.8	0	0	0	0	0.3	0.4
C12-C13	Hypopharynx	3	0	0	0.6	0	0	0	0.4	0	0	0	1	0	0	0	0	0	0	0.1	0.1
C14	Pharynx unsp. spec.	1	0	0	0	0	0	0	0	0	0	0	0	1.7	0	0	0	0	0	0	0.1
C15	Oesophagus	7	0	0	0	0	0	0	0	0	0	0	0	3.3	2.4	4.4	7.2	11.7	9.3	0.3	1.1
C16	Stomach	31	0	0	0.6	0	0	0	0	0	1	0	5	9.9	2.4	26.6	36.2	23.3	9.3	1.2	3.8
C17	Small intestine	4	0	0	0	0.6	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0.2
C18	Colon	80	0	0	0	0	0	0	1.3	0.5	2.2	3.6	12.9	6.6	21.4	44.3	43.5	46.7	101.8	3	8.5
C19-C20	Rectum	41	0	0	0	0	0	0	0	0.8	1.2	0.8	7	11.6	9.5	17.7	21.7	23.3	27.8	1.5	4
C21	Anus	6	0	0	0	0	0	0	0	0	0	1.2	0	0	2.4	8.9	0	0	0	0.2	0.5
C22	Liver	17	0	0	0.4	0	0	0.6	0	0.3	0.2	0	2	1.7	2.4	8.9	21.7	11.7	37	0.6	2.3
C23-C24	Gallbladder etc.	15	0	0	0	0	0	0	0	0	0	1.2	2	6.6	7.1	4.4	0	0	9.3	0.6	1.2
C25	Pancreas	14	0	0	0	0	0	0	0	0	0	0	1	6.6	11.9	8.9	7.2	11.7	0	0.5	1.7
C30-C31	Nose, sinuses etc.	6	0	0.3	0	0	0	0	0	0.5	0	0.4	1	1.7	2.4	0	0	0	0	0.2	0.3
C32	Larynx	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0.1
C33-C34	Trachea, Bronchus, Lung	29	0	0	0	0.6	0	0	0.4	0	0	0.4	2	3.3	14.3	35.4	21.7	11.7	37	1.1	4
C37-C38	Other Thoracic organs	2	0	0	0	0	0	0	0.9	0	0	0	0	0	0	0	0	0	0	0.1	0.1
C40-C41	Bone	13	0	0	0.4	2.2	0	1.8	0.4	0.3	0	0	2	0	4.8	4.4	0	0	0	0.5	0.7
C43	Melanoma of Skin	5	0	0	0	0	0	0	0	0.5	0	0.4	0	0	4.8	0	0	0	0	0.2	0.2
C44	Other Skin	43	0	0	0	0	0	0	1.3	0.8	1	1.2	4	8.3	16.7	17.7	14.5	46.7	37	1.6	4.4
C45	Mesothelioma	3	0	0	0	0	0	0	0	0.2	0	0	1	1.7	0	0	0	0	0	0.1	0.2
C46	Kaposi sarcoma	1	0	0	0	0	0	0.6	0	0	0	0	0	0	0	0	0	0	0	0	0
C47-C49	Connective, Soft tissue	22	0	0.3	0.4	0	1.1	0.6	0.9	0.5	0	2	2	3.3	2.4	0	7.2	11.7	9.3	0.8	1.5
C50	Breast	659	0	0	0	0.6	0.6	2.4	10.3	15.8	18.7	47.4	111.4	173.3	159.6	186.1	181.2	210	92.5	24.7	46.6
C51	Vulva	2	0	0	0	0	0	0	0	0	0	0.4	0	0	2.4	0	0	0	0	0.1	0.1
C52	Vagina	2	0	0	0	0	0	0	0	0	0.2	0	1	0	0	0	0	0	0	0	0
C53	Cervix Uteri	71	0	0	0	0	0	0	0.9	0.8	2.2	5.3	9.9	15	16.7	22.2	21.7	0	0	0.1	0.1
C54	Corpus Uteri	69	0	0	0	0	0	0.6	0	0	1	3.6	8	16.5	40.5	44.3	58	11.7	9.3	2.6	7.2
C55	Uterus unsp. spec.	14	0	0	0	0	0	0	0	0.5	0.2	0	1	6.6	2.4	8.9	21.7	0	0	0.5	1.5
C56	Ovary	66	0	0	0.6	1.8	0	1.8	0	1.1	1.5	2	9	13.2	26.2	17.7	72.5	11.7	37	2.5	6.6
C57	Other Female Genital	4	0	0	0	0	0	0.4	0	0	0	0	2	0	2.4	0	0	0	0	0.1	0.2
C58	Placenta	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
C64	Kidney	29	0	1.7	0.4	0	0.6	0	0.4	0	0.7	1.6	5	8.3	0	4.4	7.2	11.7	9.3	1.1	2
C65	Renal Pelvis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C66	Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C67	Bladder	12	0	0	0	0	0	0	0	0	0.5	0	3	3.3	2.4	4.4	0	11.7	18.5	0.4	1.2
C68	Other Urinary organs	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.2
C69	Eye	6	0	0.3	0	0	0	0	0.9	0.3	0.2	0	0	0	0	0	0	11.7	0	0.2	0.4
C70-C72	Brain, Nervous system	25	0	0.3	0.4	2.5	1.1	0	0	0	0.7	0.8	2	5	0	4.4	21.7	11.7	0	0.2	0.4
C73	Thyroid	109	0	0	0.4	1.7	4.9	5.1	6	3.7	3.7	6.5	9.9	8.3	16.7	17.7	7.2	46.7	9.3	4.1	5.7
C74	Adrenal gland	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C75	Other Endocrine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C81	Hodgkin disease	27	0	0	1.7	2.8	4.3	1.3	1.3	0.8	0	0	1	0	2.4	0	7.2	11.7	9.3	1	1.7
C82-C85;C96	Non-Hodgkin lymphoma	45	0	0	0.4	1.1	1.2	0	0	1.4	0.7	1.2	5	11.6	16.7	17.7	21.7	11.7	18.5	1.7	3.9
C88	Immunoproliferative dis.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C90	Multiple Myeloma	13	0	0	0.4	0	0	0	0	0	0	0	0	3.3	7.1	13.3	7.2	0	27.8	0.5	1.8
C91	Lymphoid Leukaemia	24	0	3.4	2.1	1.2	0.6	1.8	0	0	0	0	0	0	2.4	0	0	0	0	0.9	1
C92-C94	Myeloid Leukaemia	28	0	1	0.4	0.6	1.8	1.7	0.8	0.7	0.8	1	3.3	2.4	2.4	0	0	35	0	1	1.7
C95	Leukaemia unsp. spec.	8	0	0.4	0.4	0.6	0	0.6	0	0.3	0	0	0	5	0	0	0	0	9.3	0.3	0.6
Other	Other & unspecified	66	0	0	0.8	0	0	1.3	0.8	1.7	1.6	10.9	9.9	16.7	48.7	29	58.3	27.8	2.5	6.8	6.8
All	All sites Total	1663	0	8	4	9	15	24	29	33	41	85	228	360	426	607	652	653	620	62.3	135.3
Not C44	All sites but C44	1620	0	8	4	9	15	24	27	32	40	84	224	351	410	589	638	607	583	60.6	130.9

Table 5.5.I Number Of New Cases by Primary Site and Years among Saudi Males, 1994-2011

ICD (10th)	Site	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
C00	Lip	7	2	5	5	4	2	6	1	5	5	8	6	6	12	9	5	8	8
C01-C02	Tongue	32	15	21	24	13	25	29	14	23	29	33	38	38	40	32	42	53	44
C03-C06	Mouth	24	23	30	25	24	27	24	27	26	26	38	29	29	39	39	42	45	41
C07-C08	Salivary Glands	4	10	6	11	7	12	8	16	14	10	14	15	17	20	17	19	11	14
C09	Tonsil	4	9	2	4	6	2	1	4	5	5	2	3	0	4	2	0	2	4
C10	Other Oropharynx	2	3	3	3	1	3	0	3	3	0	2	3	0	2	2	1	2	3
C11	Nasopharynx	78	59	86	99	109	96	88	121	84	88	101	114	97	93	121	93	131	121
C12-C13	Hypopharynx	10	10	18	7	6	6	5	8	6	7	7	10	9	14	5	6	9	9
C14	Pharynx Unspecified	0	2	0	0	1	1	0	2	2	4	4	4	3	3	3	2	3	3
C15	Oesophagus	77	71	68	60	81	53	67	62	70	68	54	57	58	70	52	69	73	76
C16	Stomach	130	129	133	108	122	103	124	126	146	182	150	160	169	169	165	205	165	162
C17	Small Intestine	10	8	11	11	15	13	15	13	17	15	22	23	22	28	31	30	27	35
C18	Colon	61	87	72	85	104	101	115	120	152	177	202	260	231	270	292	344	303	378
C19-C20	Rectum	83	66	66	66	64	89	82	108	123	143	173	192	181	203	195	274	238	279
C21	Anus	10	9	7	8	6	5	10	12	14	11	17	16	16	12	12	22	18	11
C22	Liver	299	298	276	268	326	296	290	274	292	283	277	289	319	333	338	328	329	330
C23-C24	Gallbladder etc.	24	32	25	22	28	25	27	39	41	39	26	37	48	54	54	58	51	73
C25	Pancreas	50	49	53	44	60	58	68	53	75	85	82	97	101	128	102	130	114	128
C30-C31	Nose, Sinuses etc.	5	6	10	4	10	13	5	9	14	10	10	14	9	10	14	5	9	8
C32	Larynx	49	48	43	40	46	43	44	53	32	60	55	51	64	55	61	58	48	70
C33-C34	Trachea, Bronchus, Lung	188	183	184	162	223	203	197	189	194	201	253	280	237	325	294	287	292	343
C37-C38	Other Thoracic Organs	7	11	12	13	8	17	7	7	5	12	12	22	15	19	11	17	25	21
C40-C41	Bone	47	50	34	46	51	53	51	67	51	44	66	56	65	69	78	65	74	71
C43	Melanoma of Skin	21	8	8	8	6	7	11	9	12	10	13	14	12	17	13	13	12	16
C44	Other Skin	104	117	112	107	97	120	112	154	149	166	140	156	189	168	161	184	168	208
C45	Mesothelioma	5	4	5	5	7	2	7	5	3	6	6	9	8	12	18	5	9	12
C46	Kaposi Sarcoma	15	10	14	14	12	11	19	19	21	26	26	22	22	18	17	33	21	19
C47-C49	Connective Soft Tissue	85	68	51	60	50	67	55	48	63	69	59	75	64	72	72	72	69	77
C50	Breast	11	15	6	12	19	12	15	12	16	16	13	15	17	20	18	24	24	16
C60	Penis	3	4	1	8	0	1	1	1	1	1	3	5	1	3	3	2	1	0
C61	Prostate	150	148	154	123	159	150	184	170	194	192	247	272	236	259	279	305	280	311
C62	Testis	32	21	25	29	38	31	35	35	45	38	46	44	40	63	74	78	78	80
C63	Other Male Genital	1	2	0	3	1	2	3	3	3	4	3	2	4	0	0	2	2	6
C64	Kidney	69	78	56	63	71	81	73	87	91	84	124	104	120	146	158	185	167	178
C65	Renal Pelvis	5	5	0	0	10	2	6	2	1	7	8	4	5	4	5	5	5	3
C66	Ureter	1	3	1	0	3	0	4	1	0	6	3	3	1	2	3	1	1	5
C67	Bladder	165	154	127	126	152	152	155	143	160	176	175	170	174	173	178	208	193	182
C68	Other Urinary Organs	1	1	1	0	1	1	0	0	1	1	1	1	0	1	1	1	3	1
C69	Eye	21	12	18	34	16	24	26	22	24	21	21	17	28	23	27	29	22	20
C70-C72	Brain, Nervous system	131	99	126	122	101	120	139	120	120	148	155	141	155	139	162	156	148	170
C73	Thyroid	73	61	58	73	84	84	77	74	91	87	95	93	121	122	136	150	149	154
C74	Adrenal Gland	8	9	8	8	4	9	10	7	6	15	6	10	21	16	16	20	29	13
C75	Other Endocrine	2	3	5	1	2	2	1	4	1	5	3	6	5	4	9	6	0	8
C81	Hodgkin Disease	104	105	105	97	133	118	125	136	122	145	176	167	178	179	187	199	194	184
C82-C85;C96	Non-Hodgkin Lymphoma	272	214	231	226	283	268	285	246	272	329	351	351	363	425	381	436	407	432
C88	Immunoproliferative Disease	0	0	0	1	0	1	0	0	0	1	4	0	0	0	0	1	0	1
C90	Multiple Myeloma	59	41	30	36	48	37	46	36	30	39	46	60	53	46	40	62	61	50
C91	Lymphoid Leukemia	151	118	146	139	150	137	152	158	146	165	155	166	163	195	167	194	187	202
C92-C94	Myeloid Leukemia	94	90	84	103	94	109	90	129	115	90	119	109	130	119	144	147	156	148
C95	Leukemia Unspecified	10	5	5	5	8	6	14	13	12	14	13	15	26	27	37	16	16	16
Other	Other & Unspecified	147	122	98	131	140	138	126	133	153	140	149	179	181	169	155	162	161	169
All	All sites Total	2941	2697	2640	2647	3004	2938	3014	3095	3248	3505	3766	3986	4043	4391	4390	4798	4593	4913
Not.C44	All sites but C44	2837	2580	2528	2540	2907	2818	2902	2941	3099	3339	3626	3830	3854	4223	4229	4614	4425	4705

Table 5.5.2 Number Of New Cases by Primary Site and Years among Saudi Females, 1994-2011

ICD (10th)	Site	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
C00	Lip	3	3	4	2	1	5	4	3	6	5	8	6	4	5	6	8	5	7
C01-C02	Tongue	21	20	28	28	29	31	23	19	30	30	29	23	25	38	30	39	43	52
C03-C06	Mouth	23	38	37	22	32	39	25	27	29	30	21	43	36	51	46	37	48	46
C07-C08	Salivary Glands	8	7	6	3	11	8	14	8	6	10	12	13	14	18	17	21	15	22
C09	Tonsil	0	3	3	3	1	1	3	1	5	4	1	1	1	3	3	3	0	1
C10	Other Oropharynx	0	1	0	0	1	0	0	0	2	0	2	2	0	1	0	0	1	1
C11	Nasopharynx	38	27	39	31	37	36	23	41	41	39	45	35	44	56	50	42	40	45
C12-C13	Hypopharynx	19	10	14	15	19	16	10	12	12	2	16	16	10	9	17	12	17	16
C14	Pharynx Unspecified	2	3	1	1	1	1	2	0	3	1	3	0	1	3	1	3	2	2
C15	Oesophagus	75	54	68	52	44	46	55	37	58	50	51	65	62	55	56	47	50	58
C16	Stomach	67	11	64	58	66	71	62	72	77	75	76	74	115	126	103	116	126	133
C17	Small Intestine	9	11	9	10	16	10	10	14	14	11	13	13	13	14	14	25	13	35
C18	Colon	65	80	85	78	72	105	108	143	134	147	179	197	222	246	277	308	306	342
C19-C20	Rectum	44	49	52	59	57	86	72	87	104	106	118	144	142	149	163	197	186	195
C21	Anus	6	3	1	3	5	2	4	2	5	9	7	8	8	12	7	16	9	15
C22	Liver	110	88	101	86	123	93	121	101	116	129	120	114	137	130	126	150	154	158
C23-C24	Gallbladder etc.	51	37	25	31	50	59	46	55	41	60	53	68	72	85	83	90	89	90
C25	Pancreas	28	30	24	25	50	41	35	35	54	41	35	52	78	53	70	87	81	77
C30-C31	Nose, Sinuses etc.	6	9	5	4	9	8	6	5	8	2	6	10	12	13	7	7	4	3
C32	Larynx	10	2	7	10	8	10	9	2	7	4	6	6	9	10	5	18	5	6
C33-C34	Trachea, Bronchus, Lung	51	55	48	53	50	47	52	57	52	64	69	87	81	91	84	106	105	109
C37-C38	Other Thoracic Organs	7	6	5	5	5	5	8	5	3	10	9	11	11	7	12	10	11	7
C40-C41	Bone	26	38	38	25	44	37	38	43	35	39	40	41	40	30	49	46	44	58
C43	Melanoma of Skin	11	7	7	7	8	8	6	8	7	9	12	9	15	18	11	8	12	15
C44	Other Skin	78	55	87	57	83	77	80	102	95	124	131	131	134	119	126	144	151	125
C45	Mesothelioma	1	0	1	1	0	4	1	1	3	7	5	6	4	3	2	4	4	1
C46	Kaposi Sarcoma	0	3	0	8	7	8	4	5	3	6	5	8	15	6	5	10	6	6
C47-C49	Connective Soft Tissue	42	55	42	46	61	50	48	43	39	54	75	52	41	65	55	66	76	72
C50	Breast	429	434	463	464	516	514	602	565	672	713	815	952	988	1173	1215	1353	1473	1590
C51	Vulva	8	6	7	3	3	3	8	7	5	6	11	1	3	4	5	6	9	7
C52	Vagina	5	6	2	4	2	3	1	5	5	1	5	7	3	4	0	3	2	4
C53	Cervix Uteri	78	73	83	75	94	79	81	84	85	91	89	98	74	102	95	101	82	114
C54	Corpus Uteri	57	47	39	48	60	58	92	78	88	111	125	149	151	185	194	257	220	318
C55	Uterus Unspecified	3	2	9	10	16	12	5	13	14	15	13	18	24	29	22	31	29	41
C56	Ovary	96	100	96	114	107	101	104	111	108	123	119	147	139	147	172	179	175	198
C57	Other Female Genital	1	1	0	2	2	4	3	5	4	5	10	6	9	8	6	7	6	12
C58	Placenta	17	10	13	7	10	13	8	15	16	16	8	14	22	12	13	12	5	9
C64	Kidney	60	37	49	57	52	64	49	70	69	68	84	65	79	84	98	124	117	112
C65	Renal Pelvis	0	1	0	2	3	3	2	1	1	2	2	4	4	1	1	3	5	2
C66	Ureter	0	1	1	0	1	1	0	1	1	1	2	4	2	0	0	1	4	2
C67	Bladder	28	39	23	29	39	37	39	51	41	42	43	39	42	36	40	40	50	52
C68	Other Urinary Organs	0	0	0	0	0	1	1	0	0	0	1	1	0	0	1	0	2	0
C69	Eye	15	16	18	13	12	24	24	17	20	16	18	20	19	20	17	24	24	19
C70-C72	Brain, Nervous System	80	73	76	94	85	78	84	84	85	95	108	103	108	117	95	115	105	99
C73	Thyroid	207	218	198	210	264	282	259	258	279	368	346	391	432	459	496	576	548	646
C74	Adrenal Gland	10	6	10	11	9	10	14	14	10	10	17	9	9	9	13	11	14	5
C75	Other Endocrine	2	1	2	1	2	3	1	0	0	1	2	5	5	4	2	2	1	4
C81	Hodgkin Disease	59	69	59	57	74	76	87	78	76	114	105	104	119	135	136	154	142	157
C82-C85;C96	Non-Hodgkin Lymphoma	143	149	142	146	186	176	186	202	203	238	244	259	246	285	313	287	296	312
C88	Immunoproliferative Disease	0	0	0	1	0	1	1	1	0	1	0	0	0	0	0	1	0	0
C90	Multiple Myeloma	20	33	20	13	24	27	25	19	19	16	26	26	33	49	29	39	42	47
C91	Lymphoid Leukemia	76	89	80	82	73	95	112	86	101	93	85	86	92	117	118	137	113	142
C92-C94	Myeloid Leukemia	77	78	75	90	83	89	93	102	100	103	125	100	122	108	110	127	128	176
C95	Leukemia Unspecified	6	6	1	5	6	11	9	4	5	11	11	17	9	19	30	23	16	13
Other	Other & Unspecified	103	95	93	95	137	127	122	116	117	161	175	147	170	152	166	164	167	178
All	All sites Total	2381	2355	2360	2352	2750	2794	2881	2909	3107	3482	3736	4007	4249	4675	4812	5397	5378	5856
Not C44	All sites but C44	2303	2300	2273	2295	2667	2717	2801	2807	3012	3358	3605	3876	4115	4556	4686	5253	5227	5831

Table 5.5.3 Age Standardized Incidence Rate by Primary Site and Years among Saudi Males, 1994-2011

ICD (10th)	Site	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
C00	Lip	0.2	0.1	0.1	0.1	0.1	0	0.1	0	0.1	0.1	0.2	0.1	0.1	0.2	0.2	0.1	0.1	0.1
C01-C02	Tongue	0.9	0.5	0.6	0.6	0.3	0.6	0.8	0.3	0.5	0.6	0.8	0.9	0.8	0.8	0.6	0.8	1	0.7
C03-C06	Mouth	0.7	0.7	0.9	0.6	0.6	0.6	0.5	0.3	0.6	0.6	0.8	0.7	0.8	0.7	0.7	0.8	0.9	0.7
C07-C08	Salivary Glands	0.1	0.3	0.2	0.3	0.2	0.2	0.2	0.3	0.3	0.2	0.2	0.2	0.3	0.4	0.3	0.3	0.2	0.2
C09	Tonsil	0.1	0.2	0.1	0.1	0.1	0.1	0	0.1	0.1	0.1	0.1	0.1	0	0.1	0	0	0	0.1
C10	Other Oropharynx	0.1	0.1	0.1	0	0	0.1	0	0.1	0.1	0.1	0	0.1	0	0	0	0	0	0
C11	Nasopharynx	2.1	1.5	2.3	2.5	2.6	2.2	2	2.5	1.8	1.7	2	2.2	1.7	1.5	2	1.5	2	1.8
C12-C13	Hypopharynx	0.3	0.2	0.4	0.2	0.2	0.1	0.1	0.2	0.1	0.1	0.2	0.2	0.2	0.3	0.1	0.1	0.2	0.2
C14	Pharynx Unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C15	Oesophagus	2.2	1.9	1.7	1.5	2	1.2	1.5	1.6	1.6	1.6	1.2	1.3	1.4	1.4	1	1.4	1.4	1.3
C16	Stomach	3.7	3.6	3.5	2.7	3	2.4	3	2.9	3.2	4.2	3.4	3.5	4.1	3.5	3.2	4	3.1	2.8
C17	Small Intestine	0.3	0.2	0.3	0.3	0.4	0.3	0.4	0.3	0.4	0.3	0.5	0.5	0.5	0.5	0.6	0.6	0.5	0.6
C18	Colon	1.8	2.4	1.9	2.1	2.5	2.5	2.9	2.9	3.4	4	4.4	5.8	5.3	5.4	5.4	6.5	5.5	6.6
C19-C20	Rectum	2.4	1.9	1.6	1.7	1.6	2.3	2	2.4	2.6	3.3	3.9	4.4	4.3	4	3.8	5.1	4.4	4.7
C21	Anus	0.3	0.2	0.2	0.2	0.2	0.1	0.3	0.3	0.3	0.3	0.4	0.3	0.2	0.2	0.2	0.4	0.3	0.2
C22	Liver	8.7	8.6	7.5	7.1	8.4	7.5	7.3	7.3	7.1	7.1	6.6	6.8	8.3	7.2	6.9	6.6	6.4	6.1
C23-C24	Gallbladder etc.	0.7	0.9	0.7	0.6	0.7	0.6	0.7	1.1	0.9	1	0.6	0.9	1.3	1.1	1	1.1	0.9	1.3
C25	Pancreas	1.4	1.3	1.5	1.2	1.5	1.4	1.6	1.3	1.7	2	2	2.2	2.6	2.7	2	2.6	2.2	2.3
C30-C31	Nose, Sinuses etc.	0.1	0.2	0.3	0.1	0.2	0.3	0.1	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.1	0.2	0.1
C32	Larynx	1.5	1.4	1.2	1	1.2	1.1	1.1	1.5	0.8	1.5	1.3	1.3	1.6	1.2	1.2	1.2	0.9	1.3
C33-C34	Trachea, Bronchus, Lung	5.6	5.3	4.9	4.4	5.8	5.2	5	4.8	5	5.1	5.9	6.5	6.2	6.9	6	6	5.8	6.4
C37-C38	Other Thoracic Organs	0.2	0.2	0.2	0.2	0.2	0.3	0.1	0.1	0.1	0.1	0.2	0.4	0.2	0.3	0.2	0.3	0.3	0.3
C40-C41	Bone	0.7	0.7	0.5	0.7	0.7	0.7	0.7	0.8	0.6	0.6	0.7	0.6	0.7	0.7	0.9	0.7	0.7	0.8
C43	Melanoma of Skin	0.6	0.2	0.2	0.2	0.2	0.2	0.3	0.2	0.3	0.2	0.3	0.3	0.3	0.4	0.3	0.2	0.2	0.3
C44	Other Skin	2.7	3	2.8	2.8	2.4	2.7	2.5	3.5	3.2	3.7	3	3.4	4.5	3.3	3	3.5	3.1	3.6
C45	Mesothelioma	0.1	0.1	0.2	0.1	0.2	0.1	0.2	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.4	0.1	0.2	0.2
C46	Kaposi Sarcoma	0.5	0.3	0.3	0.3	0.3	0.2	0.4	0.5	0.5	0.6	0.6	0.4	0.5	0.3	0.3	0.6	0.4	0.3
C47-C49	Connective Soft Tissue	1.8	1.4	1	1.2	0.8	1.2	0.9	0.9	1.1	1.2	0.8	1	1	1	1	0.9	0.8	0.9
C50	Breast	0.3	0.4	0.1	0.3	0.5	0.3	0.4	0.3	0.4	0.4	0.3	0.3	0.4	0.4	0.3	0.4	0.4	0.3
C60	Penis	0.1	0.1	0	0.2	0	0	0	0	0.1	0	0.1	0.1	0	0	0.1	0	0	0
C61	Prostate	4	3.9	3.8	2.9	3.9	3.5	4	4.4	4.3	4.5	5.7	6.4	6.3	5.7	5.9	6.3	5.5	6
C62	Testis	0.7	0.4	0.5	0.5	0.7	0.6	0.6	0.5	0.7	0.5	0.6	0.5	0.5	0.7	0.8	0.8	0.8	0.8
C63	Other Male Genital	0	0	0	0.1	0	0	0.1	0.1	0.1	0.1	0.1	0	0.1	0	0	0	0	0.1
C64	Kidney	1.8	2	1.4	1.5	1.7	1.7	1.7	1.9	1.8	1.8	2.5	2.1	2.7	2.7	2.8	3.2	2.9	2.9
C65	Renal Pelvis	0.1	0.1	0	0	0.3	0.1	0.1	0	0	0.2	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0
C66	Ureter	0	0.1	0	0	0.1	0	0.1	0	0	0.2	0.1	0.1	0	0	0.1	0	0	0.1
C67	Bladder	4.6	4.3	3.4	3.2	3.8	3.7	3.9	3.4	3.5	4.1	4	3.7	4.2	3.5	3.7	4.1	3.6	3.3
C68	Other Urinary Organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C69	Eye	0.5	0.2	0.3	0.5	0.2	0.4	0.3	0.5	0.4	0.3	0.4	0.3	0.4	0.3	0.3	0.4	0.3	0.2
C70-C72	Brain, Nervous System	2.9	1.8	2.4	2.2	1.6	2.1	2.3	2.1	1.9	2.5	2.5	2.2	2.6	2	2.2	2.2	1.9	2.2
C73	Thyroid	2	1.5	1.5	1.8	1.9	1.7	1.6	1.6	1.9	1.7	1.8	1.6	2.1	1.9	2.1	2.2	2.3	2.2
C74	Adrenal Gland	0.1	0.1	0.2	0.1	0	0.1	0.2	0.1	0.1	0.2	0.1	0.1	0.3	0.2	0.2	0.2	0.3	0.1
C75	Other Endocrine	0.1	0.1	0.1	0	0	0	0	0	0	0.1	0	0.1	0.1	0	0.1	0.1	0	0.1
C81	Hodgkin Disease	2.1	1.9	1.7	1.5	2.2	1.9	1.8	2.1	1.9	2	2.4	2.1	2.1	2.1	2.1	2.4	2.1	1.9
C82-C85;C96	Non-Hodgkin Lymphoma	6.6	5	5.5	5	6.2	6.1	5.4	5	5.2	6.4	6.2	6.5	6.7	7.1	6.2	7	6.2	6.4
C88	Immunoproliferative Disease	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C90	Multiple Myeloma	1.8	1.1	0.8	1	1.3	1	1.1	0.9	0.6	0.9	1.1	1.3	1.3	1	0.8	1.2	1.2	0.9
C91	Lymphoid Leukemia	2.2	1.8	2.1	2.1	2.3	2	2.1	2.4	2.1	2.2	2.1	2	2.5	2.4	2.1	2.4	2.1	2.3
C92-C94	Myeloid Leukemia	1.9	1.7	1.7	2	2	1.9	1.7	2.1	2	1.5	1.9	1.6	2	1.6	2	2	2	2
C95	Leukemia Unspecified	0.2	0.1	0.1	0.1	0.2	0.1	0.3	0.3	0.2	0.3	0.2	0.2	0.5	0.4	0.6	0.3	0.2	0.2
Other	Other & Unspecified	4	3.1	2.6	3.3	3.4	3.4	2.8	3.4	3.5	3.2	3.3	3.9	4.3	3.3	3	3	2.9	2.8
All	All sites Total	75.9	67.1	63.1	61	68.7	65	65.1	67.9	67.4	73.9	76.3	80	86.6	80.6	77	84	76.7	78.8
Not.C44	All sites but C44	73.1	64.1	60.3	58.3	66.4	62.3	62.7	64.4	64.2	70.2	73.3	76.6	82.1	77.4	74	80.4	73.6	75.2

Table 5.5.4 Age Standardized Incidence Rate by Primary Site and Years among Saudi Females, 1994-2011

ICD (10th)	Site	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011
C00	Lip	0.1	0.1	0.1	0	0	0.1	0.1	0.1	0.2	0.1	0.2	0.1	0.1	0.1	0.1	0.2	0.1	0.1
C01-C02	Tongue	0.7	0.7	0.9	0.8	0.9	0.9	0.6	0.5	0.7	0.7	0.7	0.5	0.6	0.8	0.6	0.7	0.8	0.9
C03-C06	Mouth	0.7	1.2	1.1	0.7	1	1.1	0.7	0.6	0.7	0.7	0.5	0.9	0.8	1	0.9	0.7	0.8	0.8
C07-C08	Salivary Glands	0.2	0.2	0.2	0.1	0.3	0.2	0.2	0.1	0.2	0.2	0.3	0.2	0.2	0.3	0.2	0.3	0.2	0.3
C09	Tonsil	0	0.1	0.1	0.1	0	0	0.1	0	0.1	0.1	0	0	0	0	0.1	0	0	0
C10	Other Oropharynx	0	0	0	0	0	0	0	0	0.1	0	0.1	0.1	0	0	0	0	0	0
C11	Nasopharynx	0.9	0.6	1	0.7	0.9	0.8	0.4	0.7	0.8	0.7	0.9	0.7	0.8	0.9	0.8	0.7	0.6	0.6
C12-C13	Hypopharynx	0.6	0.3	0.5	0.5	0.6	0.4	0.3	0.3	0.2	0	0.4	0.4	0.2	0.2	0.3	0.2	0.3	0.3
C14	Pharynx Unspecified	0	0.1	0	0	0	0	0.1	0	0.1	0	0	0	0	0	0	0.1	0	0
C15	Oesophagus	2.7	1.8	2.2	1.7	1.4	1.4	1.5	1	1.5	1.2	1.2	1.5	1.6	1.2	1.1	0.9	1	1
C16	Stomach	2.4	2.3	2.1	1.7	1.9	2	1.6	1.7	1.8	1.8	1.7	1.7	2.7	2.5	1.9	2.2	2.3	2.3
C17	Small Intestine	0.3	0.4	0.3	0.3	0.5	0.2	0.2	0.3	0.2	0.3	0.3	0.3	0.3	0.3	0.3	0.4	0.2	0.6
C18	Colon	2.3	2.7	2.6	2.3	2.2	2.8	2.6	3.4	3	3.4	4.1	4.2	5.1	4.7	5.3	5.9	5.8	5.7
C19-C20	Rectum	1.6	1.7	1.6	1.9	1.7	2.2	1.8	2	2.3	2.5	2.6	3.1	3.2	2.9	3.2	3.8	3.4	3.3
C21	Anus	0.2	0.1	0	0.1	0.2	0	0.1	0.1	0.1	0.2	0.1	0.2	0.2	0.2	0.1	0.3	0.2	0.3
C22	Liver	3.9	3	3.3	2.9	3.8	2.7	3.2	2.7	2.8	3.3	2.9	2.6	3.3	2.8	2.6	3	3.1	2.9
C23-C24	Gallbladder etc.	1.8	1.3	0.8	1	1.6	1.7	1.3	1.4	1.1	1.5	1.2	1.6	1.7	1.9	1.7	1.9	1.8	1.6
C25	Pancreas	1.1	1.1	0.8	0.9	1.6	1.2	0.9	0.9	1.4	1	0.9	1.2	1.9	1.2	1.5	1.8	1.6	1.4
C30-C31	Nose, Sinuses etc.	0.2	0.2	0.1	0.1	0.2	0.2	0.1	0.1	0.2	0	0.1	0.2	0.3	0.2	0.1	0.1	0.1	0
C32	Larynx	0.3	0.1	0.2	0.3	0.2	0.3	0.2	0	0.2	0.1	0.1	0.1	0.2	0.2	0.1	0.4	0.1	0.1
C33-C34	Trachea, Bronchus, Lung	1.9	2	1.5	1.6	1.5	1.4	1.5	1.5	1.2	1.5	1.6	1.9	2	1.9	1.8	2.1	2.1	1.9
C37-C38	Other Thoracic Organs	0.2	0.2	0.1	0.1	0.1	0.1	0.2	0.1	0	0.1	0.2	0.2	0.2	0.2	0.1	0.2	0.1	0.1
C40-C41	Bone	0.4	0.7	0.7	0.4	0.6	0.5	0.4	0.5	0.4	0.5	0.5	0.4	0.4	0.3	0.6	0.5	0.5	0.6
C43	Melanoma of Skin	0.2	0.2	0.2	0.1	0.2	0.2	0.1	0.2	0.2	0.2	0.2	0.2	0.3	0.4	0.2	0.1	0.2	0.2
C44	Other Skin	2.7	1.7	2.7	1.8	2.4	2.1	2	2.5	2.2	2.9	3.1	2.9	3	2.5	2.4	2.8	2.8	2.2
C45	Mesothelioma	0	0	0	0	0	0.1	0	0	0.1	0.2	0.1	0.1	0.1	0.1	0	0.2	0.1	0
C46	Kaposi Sarcoma	0	0.1	0	0.3	0.2	0.2	0.1	0.1	0.1	0.1	0.1	0.2	0.4	0.1	0.1	0.1	0.1	0.1
C47-C49	Connective,Soft tissue	0.9	1.3	1	1	1.1	1	0.8	0.6	0.6	0.8	1.3	0.7	0.6	0.8	0.8	0.8	1.1	0.9
C50	Breast	13.3	13	13.2	12.5	13.8	12.4	13.5	12	13.9	14.6	16.1	18.4	18.1	20.5	20.3	23.4	24.9	23.4
C51	Vulva	0.3	0.2	0.2	0.1	0.1	0.1	0.2	0.2	0.1	0.1	0.2	0	0.1	0.1	0.1	0.1	0.1	0.1
C52	Vagina	0.2	0.2	0	0.2	0	0	0	0.1	0	0	0.1	0	0	0	0	0	0	0
C53	Cervix Uteri	2.4	2.2	2.5	2.2	2.8	2	1.9	2	1.8	1.9	1.8	2.1	1.5	1.8	1.7	1.8	1.5	1.7
C54	Corpus Uteri	2.1	1.4	1.4	1.5	2	1.6	2.5	2	2.2	2.7	3	3.5	3.8	4	4	5.4	4.6	5.8
C55	Uterus Unspecified	0.1	0.1	0.3	0.3	0.5	0.3	0.1	0.3	0.3	0.4	0.3	0.4	0.6	0.7	0.4	0.6	0.6	0.7
C56	Ovary	2.9	3	2.7	3.1	3.1	2.3	2.2	2.4	2.2	2.4	2.4	3	2.9	2.6	3.2	3.1	3	3.1
C57	Other Female Genital	0	0	0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.1	0.2	0.2	0.1	0.1	0.1	0.2
C58	Placenta	0.4	0.2	0.3	0.1	0.2	0.2	0.2	0.2	0.2	0.1	0.1	0.2	0.3	0.2	0.1	0.1	0.1	0.1
C64	Kidney	1.4	1	1.1	1.3	1.4	1.4	0.9	1.4	1.4	1.4	1.8	1.2	1.5	1.4	1.6	2	2	1.7
C65	Renal Pelvis	0	0	0	0.1	0.1	0.1	0.1	0	0	0.1	0.1	0.1	0.1	0	0	0.1	0.1	0
C66	Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C67	Bladder	0.9	1.1	0.7	0.9	1.2	1	1	1.3	1	1	1	0.8	1	0.7	0.8	0.8	1	1
C68	Other Urinary Organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C69	Eye	0.3	0.3	0.4	0.2	0.2	0.4	0.4	0.3	0.4	0.3	0.3	0.3	0.3	0.3	0.2	0.3	0.3	0.2
C70-C72	Brain, Nervous System	1.4	1.5	1.4	1.9	1.5	1.4	1.5	1.5	1.3	1.6	1.7	1.4	1.7	1.7	1.4	1.7	1.4	1.2
C73	Thyroid	5.5	5.2	4.7	4.9	5.8	5.6	4.8	4.7	4.8	6.3	5.7	6.2	6.6	6.4	7	8.1	7.5	8.1
C74	Adrenal Gland	0.2	0.1	0.1	0.1	0.1	0.1	0.2	0.1	0.2	0.2	0.2	0.1	0.1	0.1	0.1	0.1	0.2	0
C75	Other Endocrine	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C81	Hodgkin Disease	1.4	1.3	1	1.1	1.3	1.2	1.3	1.2	1.1	1.6	1.4	1.3	1.6	1.6	1.6	1.8	1.6	1.7
C82-C85-C96	Non-Hodgkin Lymphoma	4.2	4.2	4.1	3.9	5	4.1	4.1	4.4	4.4	5	4.8	5.2	5.1	5.1	5.6	5.1	5.2	4.8
C88	Immunoproliferative Disease	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C90	Multiple Myeloma	0.8	1.2	0.7	0.4	0.7	0.8	0.7	0.5	0.5	0.4	0.6	0.6	0.8	1	0.6	0.8	0.9	0.8
C91	Lymphoid Leukemia	1	1.6	1.2	1.1	1.3	1.3	1.7	1.3	1.3	1.2	1.1	1.1	1.3	1.5	1.4	1.6	1.4	1.6
C92-C94	Myeloid Leukemia	1.7	1.6	1.6	1.6	1.5	1.6	1.7	1.7	1.8	1.7	1.9	1.6	2.2	1.6	1.5	1.8	1.8	2.2
C95	Leukemia Unspecified	0.1	0.1	0	0.1	0.1	0.1	0.2	0.1	0.1	0.2	0.2	0.2	0.2	0.3	0.4	0.4	0.2	0.2
Other	Leukemia Unspecified	3.5	3.1	2.8	2.8	4.1	3.3	3.1	3	2.7	3.8	4	3.2	4	3	3.3	3.1	3.1	3
All	All sites Total	70.6	66.9	64.4	62.2	72	65.6	63.4	62.3	64.1	71.2	74.6	77.8	84.4	82.6	82.7	83.1	91.2	90.1
Not C44	All sites but C44	67.9	65.1	61.7	60.3	69.6	63.6	61.4	59.8	61.9	68.3	71.6	74.9	81.4	80.2	80.3	90.4	88.4	88


ICD10	Topography	Saudis			Non-Saudis			All
		Male	Female	Total	Male	Female	Total	Total
D001	Esophagus	1	0	1	3	0	3	4
D010, D011, D012	Colorectal	9	5	14	1	3	4	18
D013	Anus	1	1	2	0	0	0	2
D014	Small Intestine	2	0	2	0	0	0	2
D015	Bile Tract	1	0	1	1	0	1	2
D017, D097	Pancreas	1	1	2	0	0	0	2
D020	Glottis	1	1	2	0	0	0	2
D022	Bronchus	1	0	1	0	0	0	1
D037, D039, D042, D043, D044, D045, D046 D047, D049	Skin	6	6	12	5	2	7	19
D051, D050, D057, D059	Breast	1	66	67	0	25	25	92
D069, D067	Cervix	0	12	12	0	8	8	20
D070	Uteri	0	1	1	0	0	0	1
D071	Vulva	0	1	1	0	0	0	1
D072	Vagina	0	1	1	0	1	1	2
D073	Ovary	0	1	1	0	0	0	1
D074	Penis	1	0	1	0	0	0	1
D075	Prostate	1	0	1	0	0	0	1
D090	Bladder	81	16	97	39	8	47	144
D091	Kidney	2	0	2	0	0	0	2
D091	Ureter	2	0	2	0	0	0	2
D092	Eye	2	0	2	2	0	2	4
D092	Eye	0	4	4	0	1	1	5
D093	Thyroid	0	1	1	0	0	0	1
TOTAL		113	117	230	51	48	99	329

Table 6.1 Number of In Situ Cases among Saudis and Non-Saudis, 2011


ICD-0-3	Morphology	Saudis			Non-Saudis			All
		Male	Female	Total	Male	Female	Total	Total
9950	Polycythemia Vera	3	5	8	0	1	1	9
9960	Chronic Myeloproliferative Disease, NOS	6	4	10	3	0	2	12
9961	Myelofibrosis with Myeloid Metaplasia	3	2	5	0	0	0	5
9962	Essential Thrombocythemia	5	3	8	1	2	3	11
9963	Chronic Neutrophilic Leukemia	1	1	2	1	0	1	3
9964	Hypereosinophilic Syndrome	1	0	1	1	1	2	3
9980	Refractory Anemia	0	0	0	0	0	0	0
9982	Refractory Anemia with Sideroblasts	0	1	1	0	0	0	1
9983	Refractory Anemia with Excess Blasts	2	1	3	0	0	0	3
9985	Refractory Cytopenia with Multilineage Dysplasia	0	0	0	0	0	0	0
9989	Myelodysplastic Syndrome, NOS	18	7	25	2	0	2	27
	Total	39	24	63	8	4	12	75

Table 6.2 Number of Myelodysplastic Syndromes and Chronic Myeloproliferative Disorders among Saudis and Non-Saudis, 2011


PART VI
ARABIC SUMMARY



السرطانات العشرة الأكثر شيوعاً بين السعوديين في كلا الجنسين



السرطانات العشرة الأكثر شيوعاً بين البالغين السعوديين في كلا الجنسين



السرطانات العشرة الأكثر شيوعاً بين الأطفال السعوديين في كلا الجنسين

Arabic Summary of Cancer Statistics in Saudi Arabia for the Year 2011

الملخص العربي

إحصائيات السرطان في المملكة العربية السعودية لعام ٢٠١١ م

أنشئ السجل السعودي للاورام في عام ١٤١٢ هـ (١٩٩٢ م) بمستشفى الملك فيصل التخصصي ومركز الأبحاث تحت إشراف وزارة الصحة وبمشاركة من القطاعات الصحية الحكومية. يضم السجل خمسة فروع في مناطق المملكة بالإضافة الى وجود مكاتب في كل من مستشفيات الملك فيصل التخصصي ومركز الأبحاث والقوات المسلحة بالرياض ومدينة الملك عبدالعزيز الطبية بجدة وقوى الأمن بالرياض ومستشفى الملك خالد الجامعي بالرياض. وانتقل السجل الى المجلس الصحي السعودي في عام ١٤٣٥ هـ. بدأ السجل نشاطه في جمع المعلومات من شهر يناير في عام ١٩٩٤ م. حيث يتم جمع وترميز البيانات وتدخل حسب النظام المعتمد من منظمة الصحة العالمية وتحلل بشكل دوري. كما أن السجل يقوم بتزويد الجهات المختصة والباحثين بمعلومات إحصائية مفصلة بناء على طلبهم وفق نموذج خاص على صفحة السجل في الموقع الرسمي للمجلس الصحي السعودي:

<http://www.chs.gov.sa/En/HealthRecords/CancerRegistry/Pages/RequestForm.aspx>

بلغ إجمالي عدد حالات السرطان المسجلة في عام ٢٠١١ م ما مجموعه ١٤٢٢٢ حالة. من بين هذه الحالات ١٠٨٦٩ سعوديين بنسبة ٧٦.٤% و غير سعوديين ٣٣٥٣ بنسبة ٢٣.٦%. من بين السعوديين حالة ٤٩١٣ ذكور بنسبة ٤٥.٢% والإناث ٥٩٥٦ حالة بنسبة ٥٤.٨%.

سعوديين			غير سعوديين			المجموع الكلي
ذكر	انثى	المجموع	ذكر	انثى	المجموع	
4913	5956	10869	1690	1663	3353	14222

بلغ المعدل المعياري للإصابة بالسرطان في كل ١٠٠,٠٠٠ من السكان بين الرجال ٧٨.٨/١٠٠,٠٠٠ و بين النساء ٩٠.١/١٠٠,٠٠٠

السرطانات العشرة الأكثر شيوعاً بين السعوديين في كلا الجنسين:

يحتل سرطان الثدي المرتبة الأولى (١٦٠٦ حالة) بنسبة ١٤.٨% ثم سرطان القولون والمستقيم (١١٩٤ حالة) بنسبة ١١.٠% يليه سرطان الغدة الدرقية (٨٠٠ حالة) بنسبة ٧.٤% ثم السرطان اللمفاوي اللاهودجكن (٧٤٤ حالة) بنسبة ٦.٨% ثم سرطان ابيضاض الدم (٦٩٧ حالة) بنسبة ٦.٤% يليه سرطان الكبد (٤٨٨ حالة) بنسبة ٤.٥% يليه سرطان الرئة (٤٥٢ حالة) بنسبة ٤.٢% يليه السرطان اللمفاوي هودجكن (٣٤١ حالة) بنسبة ٣.١% ثم سرطان الجلد (٣٣٣ حالة) بنسبة ٣.١% وأخيراً سرطان الرحم (٣١٨ حالة) بنسبة ٢.٩%.

السرطانات العشرة الأكثر شيوعاً بين البالغين السعوديين في كلا الجنسين:

يحتل سرطان الثدي المرتبة الأولى (١٥٨٩ حالة) بنسبة ١٤.٦% ثم سرطان القولون والمستقيم (١١٩٢ حالة) بنسبة ١١.٠% يليه سرطان الغدة الدرقية (٧٩٥ حالة) بنسبة ٧.٣% ثم السرطان اللمفاوي اللاهودجكن (٦٧٧ حالة) بنسبة ٦.٢% ثم سرطان ابيضاض الدم (٤٣٣ حالة) بنسبة ٤.٠% يليه سرطان الكبد (٤٧١ حالة) بنسبة ٤.٣% يليه سرطان الرئة (٤٥٠ حالة) بنسبة ٤.١% ثم سرطان الجلد (٣٣٢ حالة) بنسبة ٣.١% ثم سرطان الرحم (٣١٨ حالة) بنسبة ٢.٩% وأخيراً سرطان البروستات (٣١٠ حالة) بنسبة ٢.٩%.

السرطانات العشرة الأكثر شيوعاً بين الأطفال السعوديين في كلا الجنسين:

يحتل سرطان ابيضاض الدم المرتبة الأولى (٢٦٤ حالة) بنسبة ٣٩.١% يليه سرطان الدماغ (٧٠ حالة) بنسبة ١٠.٤% ثم سرطان اللمفاوي هودجكن (٦٧ حالة) بنسبة ٩.٩% ثم السرطان اللمفاوي اللاهودجكن (٤٤ حالة) بنسبة ٦.٥% ثم سرطان الكلى (٤١ حالة) بنسبة ٦.١% يليه سرطان العظام (٤٠ حالة) بنسبة ٥.٩% ثم سرطان العين (٣٥ حالة) بنسبة ٥.٢% يليه سرطان الغدة الكظرية (٢٩ حالة) بنسبة ٤.٣% يليه سرطان الأنسجة الضامة (١٧ حالة) بنسبة ٢.٥% وأخيراً سرطان الكبد (١٢ حالة) بنسبة ١.٨%.



المملكة العربية السعودية
المجلس الصحي السعودي
السجل السعودي للأورام

تقرير معدل الإصابة بمرض السرطان
٢٠١١



المملكة العربية السعودية
المجلس الصحي السعودي
السجل السعودي للأورام



Kingdom of Saudi Arabia
Saudi Health Council
Saudi Cancer Registry

تقرير معدل الإصابة بمرض السرطان
٢٠١١

Cancer Incidence Report
Saudi Arabia
2011

حرر في أغسطس ٢٠١٥

August 2015